Unchanged

Summary of findings {#CD010806-sec1-0001}
===================

Summary of findings for the main comparison\'Summary of findings\' table 1**Group therapy (cognitive behavioural therapy (CBT)) versus control for improving psychological well‐being in adults living with HIVPatient or population:** adults living with HIV **Settings:** any setting **Intervention:** group therapy based on CBT**OutcomesIllustrative comparative risks (95% CI)\*Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlGroup therapy (CBT)Depression score** Follow‐up: 6 to 15 monthsThe mean scores in the control groups at the end of follow‐up ranged from normal to moderately depressedThe mean score in the intervention groups was: **0.26 standard deviations (SDs) lower** (0.42 lower to 0.10 lower)1139 (10 trials)⊕⊕⊝⊝ **low**^1,2,3,4^\
due to indirectness and risk of biasThere may be a small benefit which lasts for up to 15 months**Anxiety score**\
Follow‐up: 6 to 15 monthsThe mean scores in the control groups at the end of follow‐up ranged from normal to clinically anxiousThe mean score in the intervention groups was: **0.12 SDs lower** (0.31 lower to 0.06 higher)471 (4 trials)⊕⊕⊝⊝ **low**^2,5,6,7^\
due to indirectness and risk of biasThere may be little or no effect on mean anxiety scores**Stress score**\
Follow‐up: 6 to 15 monthsThe mean score in the control groups at the end of follow‐up were variableThe mean score in the intervention groups was **0.04 SDs lower** (0.23 lower to 0.15 higher)507 (5 trials)⊕⊕⊝⊝ **low**^2,5,6,7^\
due to indirectness and risk of biasThere may be little or no effect on mean stress scores**Coping score**\
Follow‐up: 6 to 15 monthsThe mean score in the control groups at the end of follow‐up were variableThe mean score in the intervention groups was **0.04 SDs higher** (0.11 lower to 0.19 higher)697 (5 trials)⊕⊕⊝⊝ **low**^2,5,6,7^\
due to indirectness and risk of biasThere may be little or no effect on mean coping scoresStudies used a variety of different scales to measure depression, anxiety and stress. Consequently, trials were pooled using a standardized mean difference. Examples of how large this effect would be on standardized measurement scales are given in the review main text and abstract. **Abbreviations:** CBT: cognitive behavioural therapy; CI: confidence interval; SD: standard deviation.GRADE Working Group grades of evidence **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^2]

Summary of findings 2\'Summary of findings\' table 2**Group therapy (mindfulness) compared to control for improving psychological well‐being in adults living with HIVPatient or population:** adults living with HIV **Settings:** any setting **Intervention:** group therapy based on mindfulness**OutcomesIllustrative comparative risks\* (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlGroup therapy (Mindfulness)Depression score**\
Follow‐up: 4 to 6 monthsThe mean scores in the control groups at the end of follow‐up were in the range of normal to mild depressionThe mean score in the intervention groups was **0.23 standard deviations (SDs) lower** (0.49 lower to 0.03 higher)233 (3 trials)⊕⊝⊝⊝ **very low**^1,2,3,4^\
due to risk of bias, indirectness, and imprecisionWe don\'t know if there is a benefit on depression scores**Anxiety score**\
Follow‐up: 4 to 6 monthsThe mean scores in the control group at the end of follow‐up were in the range of normal to mild anxietyThe mean score in the intervention groups was **0.16 SDs lower** (0.47 lower to 0.15 higher)162 (2 trials)⊕⊝⊝⊝ **very low**^1,3,4^\
due to risk of bias, indirectness, and imprecisionWe don\'t know if there is an effect on mean anxiety scores**Stress score**\
Follow‐up: 4 to 6 monthsThe mean scores in the control group at the end of follow‐up were in the range of mild stressThe mean score in the intervention groups was **2.02 points lower** (4.23 lower to 0.19 higher)137 (2 trials)⊕⊝⊝⊝ **very low**^1,3,4^\
due to risk of bias, indirectness, and imprecisionWe don\'t know if there is an effect on mean stress scores**Coping score**\
Follow‐up: no coping was measured by mindfulness intervention trials------0\
(0 trials)------Studies used a variety of different scales to measure depression, anxiety and stress. Consequently, trials were pooled using a standardized mean difference. Examples of how large this effect would be on standardized measurement scales are given in the review main text and abstract. **Abbreviations:** CI: confidence interval; OR: odds ratio; SD: standard deviation.GRADE Working Group grades of evidence **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^3]

Background {#CD010806-sec1-0002}
==========

Description of the condition {#CD010806-sec2-0001}
----------------------------

Infection with the human immunodeficiency virus (HIV) causes a chronic, life‐threatening disease, characterized by progressive destruction of the immune system and increasing susceptibility to infection and malignancy. Consequently, despite the availability of highly active antiretroviral therapy (HAART), which has revolutionized treatment, a new diagnosis of HIV carries multiple threats to a person\'s psychological well‐being ([@CD010806-bbs2-0107]; [@CD010806-bbs2-0103]; [@CD010806-bbs2-0094]). Being labelled with a chronic illness, especially one associated with the stigma of HIV, and the accompanying need to take multiple daily medications with unpleasant side effects can lead to uncertainty about the future, relationship difficulties, social isolation, and loss of self esteem. Failure to adjust can in turn lead to clinical depression, anxiety, stress, and poor coping ([@CD010806-bbs2-0124]). Particularly, the prevalence of depression and suicide in people living with HIV/AIDS is very high ([@CD010806-bbs2-0095]; [@CD010806-bbs2-0116]; [@CD010806-bbs2-0089]; [@CD010806-bbs2-0087]).

Description of the intervention {#CD010806-sec2-0002}
-------------------------------

Psychosocial group interventions, by definition, include some form of psychological therapy such as cognitive behavioural therapy (CBT) delivered in a group format. However, many will also include additional components that may also have effects on psychological well‐being, such as: relaxation techniques and stress management; problem solving and coping skills; social or peer support; and education and empowerment (see [Figure 1](#CD010806-fig-0001){ref-type="fig"}).Figure 1Conceptual framework

How the intervention might work {#CD010806-sec2-0003}
-------------------------------

Psychological well‐being is usually conceptualized as some combination of positive affective states such as happiness and functioning, with optimal effectiveness in individual and social life ([@CD010806-bbs2-0097]). As summarized by [@CD010806-bbs2-0104] (p.137): "Psychological well‐being is about lives going well. It is the combination of feeling good and functioning effectively". By definition therefore, people with high psychological well‐being report feeling happy, capable, well‐supported, and satisfied with life.

Fundamentals to psychological well‐being for HIV‐positive people are positive coping strategies and perceived social support ([@CD010806-bbs2-0098]; [@CD010806-bbs2-0024]; [@CD010806-bbs2-0123]). As compared to individual therapy, group therapy is believed to confer a wider range of psychosocial benefits. In a well‐functioning group, members may give and receive motivational support and encouragement for self‐efficacy, and through shared experiences can empower each other to access services, adhere to treatment, and cope with stigma and stress ([@CD010806-bbs2-0106]; [@CD010806-bbs2-0110]; [@CD010806-bbs2-0111]; [@CD010806-bbs2-0099]; [@CD010806-bbs2-0125]; [@CD010806-bbs2-0113]). This is contrasted with the problem of stigma inherent in joining groups defined by HIV‐status ([@CD010806-bbs2-0117]). Being in a group helps participants to feel they are not alone in dealing with their problems and also encourages relating to yourself and others in healthier ways. Group formats are also cost effective and resource effective, reaching more patients than individual or one‐on‐one therapies. This is advantageous, particularly in resource‐poor settings.

Why it is important to do this review {#CD010806-sec2-0004}
-------------------------------------

A positive diagnosis of HIV means a lifetime of medical treatment, but also dealing with the psychological effects of living with a chronic disease. Psychosocial interventions focus on stress management, coping, and self efficacy and have the potential to have a positive effect on peoples\' mental health and treatment adherence. However, the evidence base of what works to improve the psychological well‐being of people living with HIV, particularly those in high‐risk groups and those living in resource‐poor settings, is lacking. In order to inform practice and research, this Cochrane Review can contribute to evidence on what types of psychosocial interventions are most effective to improve psychological well‐being for HIV‐positive adults. Certainty of the evidence is also important to define future studies, and whether findings are consistent and can be generalized across populations and settings.

Objectives {#CD010806-sec1-0003}
==========

To examine the effectiveness of psychosocial group interventions for improving the psychological well‐being of adults living with HIV/AIDS.

Methods {#CD010806-sec1-0004}
=======

Criteria for considering studies for this review {#CD010806-sec2-0005}
------------------------------------------------

### Types of studies {#CD010806-sec3-0001}

Randomized controlled trials (RCTs) or quasi‐RCTs with at least three months follow‐up post‐intervention.

### Types of participants {#CD010806-sec3-0002}

HIV‐positive adults with and without current psychological illness.

### Types of interventions {#CD010806-sec3-0003}

Any psychosocial intervention delivered in a group format that aims to improve the psychological well‐being of people living with HIV. This might include the following types of interventions.

Interventions conducted in hospitals, clinics, or community settings.Interventions delivered face‐to‐face or via telephone or video link.Interventions focused on providing information and psychoeducation, cognitive restructuring, stress appraisal and management, relaxation and mindfulness, adaptive and productive coping, assertiveness training and social support.Interventions based on any theoretical approach.

The control intervention may be standard care, a waiting list for future intervention, or a brief educational/psychosocial intervention delivered in‐group or individual format.

### Types of outcome measures {#CD010806-sec3-0004}

#### Primary outcomes {#CD010806-sec4-0001}

Improved psychological well‐being of HIV‐positive people measured by decreases in depression scores using validated scales.

#### Secondary outcomes {#CD010806-sec4-0002}

Measures of anxiety using validated scales.Measures of stress using validated scales.Measures of coping using validated scales.

All outcomes must be measures at baseline, post‐intervention and at a time point at least three months after the intervention.

Search methods for identification of studies {#CD010806-sec2-0006}
--------------------------------------------

The HIV/AIDS Information Specialist, Joy Oliver, assisted the review author team to identify trials for inclusion in the review.

### Electronic searches {#CD010806-sec3-0005}

We searched the following electronic databases up to 14 March 2016 using the search strategy presented in [Appendix 1](#CD010806-sec2-0016){ref-type="app"}: the Cochrane Central Register of Controlled Trials (CENTRAL) published in the Cochrane Library (Issue 2, 2016), PubMed (MEDLINE) (1996 to 14 March 2016), and Embase (1996 to 14 March 2016). We also checked Clinical Trials.gov using the search terms in [Appendix 2](#CD010806-sec2-0017){ref-type="app"}.

### Searching other resources {#CD010806-sec3-0006}

We searched the reference list of all papers that matched our inclusion criteria and contacted the first authors to identify any other trial analyses that were published.

Data collection and analysis {#CD010806-sec2-0007}
----------------------------

### Selection of studies {#CD010806-sec3-0007}

Two review authors (IVDH and NA) independently screened the abstracts of all citations identified by the literature search to see if any met the inclusion criteria. If an abstract was potentially relevant, or it was unclear whether it was relevant or not, we accessed the full‐text paper and read it carefully to see if it the trial met the inclusion criteria. Regarding multiple reports of the same trial, we linked these, collated the data available in the reports, and presented these as one trial. We listed all excluded studies and their reasons for exclusion in the \'[Characteristics of excluded studies](#CD010806-sec2-0022){ref-type="sec"}\' table. We constructed a PRISMA study flow diagram to illustrate the study selection process.

### Data extraction and management {#CD010806-sec3-0008}

Two review authors (IVDH and NA) independently extracted data from the included trials using a standardized data extraction form that included the following characteristics: citation of authors and year, the type of trial design, population characteristics and trial setting, eligibility criteria, type of intervention, treatment and control group duration and components, all relevant outcomes with measures (scales), time assessment points, percentage lost to follow‐up and results, see [Appendix 3](#CD010806-sec2-0018){ref-type="app"}.

### Assessment of risk of bias in included studies {#CD010806-sec3-0009}

Two review authors (IVDH and NA) independently assessed the risk of bias of all trials included in the review using the Cochrane \'Risk of bias\' assessment tool ([@CD010806-bbs2-0100]; [@CD010806-bbs2-0101]). We resolved any discrepancies through discussion and by consulting the third review author, and if necessary we contacted the trial authors for clarification.

We followed the guidance to assess whether the included trials took adequate steps to reduce the risk of bias across the following six domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias.

For sequence generation and allocation concealment, we reported the methods that the included trials used. For blinding, we described who was blinded and the blinding method. For incomplete outcome data, we reported the percentage of participants lost to follow‐up. For selective outcome reporting, we stated any discrepancies between the methods used and the results in terms of the outcomes measured or the outcomes reported. For other biases, we described any other trial features that could have affected the trial result (for example, if the trial was stopped early, or how the use of a wait‐list group may bias results because waiting‐list controls might be biased because of resentment at not receiving an intervention, changes in disease state over time, and an absence of engagement in care. However, blinding and randomization will balance out this bias risk.

We categorized our risk of bias judgements as either \'low\', \'high\', or \'unclear\'. Where risk of bias was unclear, we attempted to contact the trial authors for clarification and resolved any differences of opinion through discussion.

### Measures of treatment effect {#CD010806-sec3-0010}

We reported results using mean difference (MD) with 95% confidence intervals (95% CI), and used standardized mean difference (SMD) values when we pooled trials using different scales.

### Unit of analysis issues {#CD010806-sec3-0011}

The unit of analysis in all trials was the individual (HIV‐positive adult). For complicated designs, such as cluster‐RCTs, we planned to use the cluster as the unit of analysis, and planned to account for clustering by adjusting the analysis to the same level as the individual following the guidelines in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD010806-bbs2-0100]; [@CD010806-bbs2-0101]).

When trials had more than two treatment arms we took care to avoid double counting of participants in the control group.

### Dealing with missing data {#CD010806-sec3-0012}

Our primary analysis was a complete‐case analysis, which included only the participants with data at each time point.

We considered the potential for bias due to missing data in our GRADE evaluation of the certainty of the evidence, by considering the size of losses to follow‐up, and any differential losses between groups.

We contacted trial authors for clarification regarding missing data.

### Assessment of heterogeneity {#CD010806-sec3-0013}

We described clinical heterogeneity between trials by summarizing key characteristics of the trial design, intervention, population, and outcome measures in tables.

We assessed statistical heterogeneity by looking at forest plots to examine the presence of overlapping CIs and using the Chi² test using a P value of 0.10 to determine statistical significance. We quantified heterogeneity using the I² statistic, which describes the percentage of variability in the effect estimates and we applied the standard categorization of heterogeneity to interpret the statistic i.e. low heterogeneity = I² statistic value of 0% to 25%; moderate heterogeneity = I² statistic value of 26% to 50% and high heterogeneity = I² statistic value of greater than 50%.

### Assessment of reporting biases {#CD010806-sec3-0014}

We planned to use funnel plots to look for evidence of publication bias. However, there were few included trials to facilitate this.

### Data synthesis {#CD010806-sec3-0015}

We summarized and analysed the included trials in Review Manager 5 (RevMan 5) ([@CD010806-bbs2-0115]).

We analysed trials with different underlying psychological theories separately, and stratified the primary analysis by time point: baseline, end of the group session, and longest follow‐up.

When pooling studies was considered appropriate we used a random‐effects approach due to the clinical heterogeneity between trials.

We created a \'Summary of findings\' for each comparison including the four main outcomes: depression, anxiety, stress, and coping. For each effect estimate we evaluated our confidence in the effect by considering each of the five GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness, and publication bias. When we found sufficient problems to downgrade the overall certainty of the evidence we justified these decisions using footnotes.

### Subgroup analysis and investigation of heterogeneity {#CD010806-sec3-0016}

We explored possible causes of statistical heterogeneity by conducting sub group analyses by: primary focus of the intervention, outcome scale used, the control intervention, and gender. We only performed these subgroup analyses when there were sufficient trials to make it meaningful.

### Sensitivity analysis {#CD010806-sec3-0017}

We did not plan to perform any sensitivity analysis.

Results {#CD010806-sec1-0005}
=======

Description of studies {#CD010806-sec2-0008}
----------------------

### Results of the search {#CD010806-sec3-0018}

We searched the available literature up to 14 March 2016 and identified 2414 citations from the electronic database searches. After discarding 1376 duplicates, we screened 1038 articles by title and abstract. We selected abstracts that potentially matched our inclusion criteria, and also articles where it was unclear whether or not they fulfilled the inclusion criteria, for full‐text assessment. We excluded 942 articles and identified 96 full‐text articles for further assessment. After full‐text assessment of these articles. we excluded 77 articles. These corresponded to 70 studies after we collated them, which we listed in the \'[Characteristics of excluded studies](#CD010806-sec2-0022){ref-type="sec"}\' table. Nineteen articles met the inclusion criteria. We collated multiple reports on the same trial, which gave 16 included trials. We have illustrated the study selection process in [Figure 2](#CD010806-fig-0002){ref-type="fig"}.Figure 2Study flow diagram

### Included studies {#CD010806-sec3-0019}

Sixteen randomized controlled trials (RCTs) that included 2520 HIV‐positive adults met the inclusion criteria of this Cochrane Review. Four trials exclusively recruited homosexual men ([@CD010806-bbs2-0006]; [@CD010806-bbs2-0005]; [@CD010806-bbs2-0001]; [@CD010806-bbs2-0008]), and two trials recruited women only ([@CD010806-bbs2-0002]; [@CD010806-bbs2-0011]). The remaining trials recruited both men and women, with four specifying they were all on antiretroviral therapy (ART) ([@CD010806-bbs2-0003]; [@CD010806-bbs2-0007]; [@CD010806-bbs2-0014]; [@CD010806-bbs2-0015]), one trial recruited only those with a history of childhood sexual abuse ([@CD010806-bbs2-0016]), one recruited injection drug users ([@CD010806-bbs2-0015]), one recruited those over 50 years old ([@CD010806-bbs2-0010]), and one recruited participants with major depression ([@CD010806-bbs2-0013]). All trials excluded pregnant women (see [Table 5](#CD010806-tbl-0005){ref-type="table"}).Table 1Description of populations**TrialCountryAge (years)On antiretroviral therapy (ART)General population or subgroupMood disordersInclusion criteriaExclusion criteria**[@CD010806-bbs2-0001]USA18 to 65YesHomosexual menNone statedCurrent psychosis or panic disorder[@CD010806-bbs2-0002]USA18 to 60Not statedWomen with evidence of CIN1None statedCurrent major psychiatric illness[@CD010806-bbs2-0003]Switzerland18 to 65YesGeneral populationNone statedCurrent major psychiatric disorder[@CD010806-bbs2-0005]USANot statedNo (recruited\
largely during the era prior to highly active antiretroviral therapy (HAART; 1992 to 1997)Homosexual menNone statedCurrent major psychiatric illness[@CD010806-bbs2-0011]USA\> 18Not statedMinority womenNone statedUntreated major psychiatric illness[@CD010806-bbs2-0012]USA\> 18YesGeneral populationNone statedSignificant psychiatric illness[@CD010806-bbs2-0015]USA18 to 65YesPrior intravenous drug usersCurrent depressive mood disorderUntreated or unstable major mental illness[@CD010806-bbs2-0009]USANot statedNot statedRural populationNo inclusion or exclusion criteria related to psychological functioning were employedNo inclusion or exclusion criteria related to psychological functioning were employed[@CD010806-bbs2-0010]USA\> 50Not statedIndividuals over the age of 50BDI‐II score is minimum 10Exclude severe depression or cognitive impairment[@CD010806-bbs2-0016]USANot statedNot statedHistory of child sexual abuseNot statedNot stated[@CD010806-bbs2-0014]South Africa\> 18YesIndividuals with ART adherence problem/new antiretroviral (ARV) medication users (6 to 24 months of ARV use)Not statedNot stated[@CD010806-bbs2-0006]USA21 to 60NoHomosexual menReported depressed mood 10 or higher on CES‐D scaleMajor depressive disorder or other psychotic disorders[@CD010806-bbs2-0004]USA18 to 65Not statedAdult men and women (50% homosexual)Not statedCognitive impairment of active psychosis[@CD010806-bbs2-0007]USANot specifiedYesAdult men and women who reported distress associated with side effects from ART treatmentReporting a level of side effect‐related bother for the previous 30 days at or above eight (corresponding to the 40th percentile in another sample) on the side effect and symptom distress scaleSevere cognitive impairment, active psychosis, or active substance abuse[@CD010806-bbs2-0008]CanadaNot specifiedNot statedHomosexual menNone statedActive current major depression, substance abuse, or significant cognitive deficit[@CD010806-bbs2-0013]Uganda\> 19Not statedBoth men and womenPeople with major depression on Mini Psychiatric Interview ScaleThe trial excluded individuals with a severe medical disorder such as pneumonia or active tuberculosis, psychotic symptoms, and hearing or visual impairment.[^4]

Twelve trials were conducted in the USA ([@CD010806-bbs2-0006]; [@CD010806-bbs2-0012]; [@CD010806-bbs2-0005]; [@CD010806-bbs2-0001]; [@CD010806-bbs2-0004]; [@CD010806-bbs2-0009]; [@CD010806-bbs2-0002]; [@CD010806-bbs2-0011]; [@CD010806-bbs2-0010]; [@CD010806-bbs2-0007]; [@CD010806-bbs2-0015]; [@CD010806-bbs2-0016]), Canada ([@CD010806-bbs2-0008]), and one in Switzerland ([@CD010806-bbs2-0003]), one in Uganda ([@CD010806-bbs2-0013]) and one in South Africa ([@CD010806-bbs2-0014]). Recruitment was from hospitals, clinics, drop‐in centres, or community settings.

Therapy was conducted with groups of four to 15 people every week for up to 12 weeks. All were face‐to‐face interventions except in [@CD010806-bbs2-0009] and [@CD010806-bbs2-0010] in which they were delivered by telephone. All interventions were delivered by postgraduate trained health, psychology, or social care professionals, except one which used lay health workers ([@CD010806-bbs2-0014]). Sessions lasted 90 to 135 minutes, and the period of follow‐up varied from three to 15 months. The control groups ranged from wait‐list, standard care or treatment as usual, information or education only, or a brief form of the intervention (30 minutes or one day).

We subgrouped the interventions by their underlying psychological theory, although all the interventions were multifaceted.

Cognitive behavioural therapy (CBT) (13 trials): a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviours, and cognitive processes through a number of goal‐oriented, problem‐focused, action‐orientated procedures. The name refers to therapy based upon a combination of basic behavioral and cognitive principles and research. Most therapists working with patients dealing with anxiety and depression use a blend of cognitive and behavioral therapy. Six trials focused particularly on stress management ([@CD010806-bbs2-0012]; [@CD010806-bbs2-0005]; [@CD010806-bbs2-0001]; [@CD010806-bbs2-0002]; [@CD010806-bbs2-0003]; [@CD010806-bbs2-0016]), three on coping ([@CD010806-bbs2-0006]; [@CD010806-bbs2-0009]; [@CD010806-bbs2-0010]), one on self‐efficacy ([@CD010806-bbs2-0011]), one on adherence and depression ([@CD010806-bbs2-0015]), one on depression ([@CD010806-bbs2-0013]), and one on adherence ([@CD010806-bbs2-0014]).Mindfulness Based Stress Reduction (three trials): a structured group programme that employs mindfulness meditation to enhance awareness of irrational thoughts and negative affect ([@CD010806-bbs2-0007]; [@CD010806-bbs2-0008]), and includes a spirituality approach that involves repeating a mantram‐sacred word or phrase ([@CD010806-bbs2-0004]).

The trials reported a variety of scales for depression, anxiety, stress, and coping ([Table 6](#CD010806-tbl-0006){ref-type="table"}; [Table 7](#CD010806-tbl-0007){ref-type="table"}; [Table 8](#CD010806-tbl-0008){ref-type="table"}). We pooled these data using standardized mean differences, before presenting a subgroup analysis using the same assessment scale.Table 2Depression scales reported by trials**ScaleNumber of items (depression)Scale for each item^1^Total score (depression)InterpretationDescription^2^Trials**Beck Depression Inventory (BDI/BDI‐II) ([@CD010806-bbs2-0088])210 (I do not) to 3 (I do and I can\'t stand it)0 to 630 to 13: minimal\
14 to 19: mild\
20 to 28: moderate\
29 to 63: severeParticipants rate the intensity of depressive feelings over the preceding 1 or 2 weeks[@CD010806-bbs2-0005]; [@CD010806-bbs2-0001]; [@CD010806-bbs2-0009]; [@CD010806-bbs2-0011]; [@CD010806-bbs2-0007]; [@CD010806-bbs2-0014]; [@CD010806-bbs2-0015]Hospital Anxiety and Depression Scale (HADS) ([@CD010806-bbs2-0127])70 (not at all) to 3 (very often)0 to 210 to 7: normal\
8 to 10: borderline\
11 to 21: depressionParticipants rate the frequency of depressive thoughts and behaviours over the preceding 4 weeks[@CD010806-bbs2-0003]; [@CD010806-bbs2-0008]Geriatric Depression Scale (GDS) ([@CD010806-bbs2-0126])300 (no) to 1 (yes)0 to 300 to 9: normal\
10 to 19: mild\
20 to 30: severeParticipants report the presence or absence of depressive thoughts and behaviours[@CD010806-bbs2-0010]The Centre for Epidemiological Studies‐Depression Scale (CES‐D) ([@CD010806-bbs2-0114])200 (not at all) to 3 (all of the time)0 to 600 to 15: normal\
16 to 60: depression\
Cut off is 16Participants rate the frequency of depressive symptoms, feelings, and behaviours over the past week[@CD010806-bbs2-0006]; [@CD010806-bbs2-0004]Self Reported Questionnaire (SRQ‐20) ([@CD010806-bbs2-0120])200 (no) to 1 (yes)0 to 200 to 5: normal\
6 to 20: depressionParticipants report the presence or absence of depressive symptoms, thoughts, and behaviours[@CD010806-bbs2-0013]Profile of Mood States (POMS) Depression (D)\
([@CD010806-bbs2-0109])150 (not at all) to 4 (extremely)0 to 60Higher scores indicate worsening depressionParticipants rate adjectives describing their mood states over the past week[@CD010806-bbs2-0001]^3^Montgomery‐Asberg Depression Rating Scale (MADRS) ([@CD010806-bbs2-0112])100 (normal) to 6 (severe)0 to 600 to 6: normal\
7 to 19: mild\
20 to 34: moderate\
\> 34: severeA physician assessment based on a clinical interview covering depression symptoms[@CD010806-bbs2-0015]^3^[^5]Table 3Anxiety scales reported by the included trials**ScaleNumber of items (anxiety)Score for each item^1^Total score (anxiety)InterpretationDescription^2^Trials**Profile of Mood States (POMS) Anxiety (A)\
([@CD010806-bbs2-0109])90 (not at all) to 4 (extremely)0 to 36Higher scores indicate worsening anxietyParticipants rate adjectives describing their mood states over the past week[@CD010806-bbs2-0001]Hospital Anxiety and Depression Scale (HADS) ([@CD010806-bbs2-0127])70 (not at all) to 3 (very often)0 to 210 to 7: normal\
8 to 10: borderline\
11 to 21: anxietyParticipants rate the frequency of anxiety feelings and behaviours over the preceding 4 weeks[@CD010806-bbs2-0003]; [@CD010806-bbs2-0008]State Trait‐Anxiety Inventory (STAI) ([@CD010806-bbs2-0122])201 (not at all) to 4 (very much so)20 to 80A cut point of 39 to 40 has been suggested to detect clinically significant symptomsParticipants rate the frequency and intensity of anxiety feelings at this moment (state), and more generally (trait)[@CD010806-bbs2-0006]; [@CD010806-bbs2-0004]; [@CD010806-bbs2-0011][^6]Table 4Stress scales reported by trials**ScaleNumber of itemsScore for each item^1^Total scoreInterpretationDescription^2^Trials**Perceived Stress Scale (PSS) ([@CD010806-bbs2-0093])100 (never) to 4 (very often)0 to 40Higher scores indicate higher perceived stressParticipants rate the frequency of stress related thoughts and feelings in the preceding 4 weeks[@CD010806-bbs2-0006]; [@CD010806-bbs2-0004]; [@CD010806-bbs2-0007]Dealing with Illness Scale ‐ Stress subscale (DIS) ([@CD010806-bbs2-0108])UnclearUnclearUnclearHigher scores reflect higher stressParticipants rate the desirability or undesirability and personal impact of experienced events[@CD010806-bbs2-0012]HIV‐Related Life‐Stress Scale ([@CD010806-bbs2-0121])191 (not a problem) to 5 (most serious problem)1 to 5Higher scores indicate higher stressParticipants rate the severity of each HIV‐related potential stressor[@CD010806-bbs2-0009]Life Experiences Survey (LES) ([@CD010806-bbs2-0118])100 (not at all stressed) to 3 (extremely stressful)0 to 30 = not at all stressed\
1 = mildly stressed\
2 = moderately stressed\
3 = extremely stressedParticipants rate the extent to which an event commonly experienced by HIV‐positive women had been stressful[@CD010806-bbs2-0002] (a 10‐item abbreviated version)Impact of Event Scale (IES)\
([@CD010806-bbs2-0102])150 (not at all) to 4 (often)0 to 75Higher scores indicate higher impactParticipants rate the frequency of intrusive or avoidant thoughts and experiences over the preceding 7 to 28 days (the authors describe this scale as measuring \'psychological distress\' or \'traumatic stress\')[@CD010806-bbs2-0012]; [@CD010806-bbs2-0008]; [@CD010806-bbs2-0016][^7]

### Excluded studies {#CD010806-sec3-0020}

We excluded a total of 70 trials (77 articles) after full‐text assessment and listed the reasons for exclusion in the \'[Characteristics of excluded studies](#CD010806-sec2-0022){ref-type="sec"}\' table. Some studies were not RCTs or did not report on RCT data, and most studies did not include group interventions; this was not apparent when we only assessed the abstract. Other trials did not have at least a three‐month post‐intervention follow‐up assessment. [@CD010806-bbs2-0072] invited the control to cross‐over to the intervention after three months but had no post‐intervention three‐month follow‐up. For example, we excluded [@CD010806-bbs2-0083] as we did not receive any response from the study author about what data they included in the post‐intervention period, that is whether the data presented in this trial was the three‐month or six‐month follow‐up data; it remains unclear. [@CD010806-bbs2-0046] and [@CD010806-bbs2-0084] did not have HIV‐positive populations. Six trials did not measure our specified outcomes. One trial, [@CD010806-bbs2-0045], presented a subgroup analysis from a larger trial. [@CD010806-bbs2-0061] had a sample of adolescents and not adults. [@CD010806-bbs2-0071] did not report on effects for the group intervention.

We excluded seven trials conducted in Africa: [@CD010806-bbs2-0059] in Western Kenya measured reductions in alcohol use in people on antiretroviral (ARV) treatment using a CBT intervention so did not include a specified outcomes, [@CD010806-bbs2-0057] in Nigeria measured psychological distress, risky sexual behaviour, and self‐disclosure of HIV using an individual psychoeducation intervention rather than a group intervention, [@CD010806-bbs2-0054] measured rates of disclosure and active and avoidant coping in pregnant and recently diagnosed HIV‐positive women in South Africa participating in structured up support groups, but this was not an RCT. [@CD010806-bbs2-0060]\'s trial on a group‐based counselling intervention for depression in South Africa did not have a three‐month follow‐up postintervention. [@CD010806-bbs2-0060] also had a very small sample size. [@CD010806-bbs2-0044]\'s trial was based in Uganda but was a treatment supporter intervention and not a group intervention, and [@CD010806-bbs2-0040]\'s trial among HIV positive women in Zambia did not have a control group. [@CD010806-bbs2-0041]\'s trial in Tanzania measured prenatal HIV disclosure and depression, however we excluded it because there was no three‐month post‐intervention follow‐up.

Risk of bias in included studies {#CD010806-sec2-0009}
--------------------------------

For a summary of the \'Risk of bias\' assessments see [Figure 3](#CD010806-fig-0003){ref-type="fig"} and [Figure 4](#CD010806-fig-0004){ref-type="fig"}.Figure 3\'Risk of bias\' summary: review authors\' judgements about each \'Risk of bias\' item for each included trialFigure 4\'Risk of bias\' graph: review authors\' judgements about each \'Risk of bias\' item presented as percentages across all included trials

### Allocation {#CD010806-sec3-0021}

We only included \'randomized\' trials. However, only [@CD010806-bbs2-0003] provided enough detail of the methods to be considered at low risk of selection bias. All other included trials were at unclear risk of selection bias.

### Blinding {#CD010806-sec3-0022}

True blinding of participants to the types of interventions evaluated in this review is rarely possible. Trial authors did not describe blinding sufficiently. However, it is possible to blind those conducting the analysis but only one trial described the methods to achieve this and we judged it to be at low risk of detection bias ([@CD010806-bbs2-0015]). All other trials were at unclear risk of detection bias.

### Incomplete outcome data {#CD010806-sec3-0023}

Fourteen trials reported high levels of loss to follow‐up in at least one treatment arm over the duration of the trial (greater than 20%), or differential losses between groups, which had the potential to bias the results. Consequently we only judged two included trials to be at low risk of attrition bias ([@CD010806-bbs2-0007]; [@CD010806-bbs2-0014]).

### Selective reporting {#CD010806-sec3-0024}

We found no evidence of selective reporting and we considered all included trials as at low risk of reporting bias.

### Other potential sources of bias {#CD010806-sec3-0025}

[@CD010806-bbs2-0004] and [@CD010806-bbs2-0015] noted some imbalances in potential confounders between the intervention and control groups at baseline. We judged these trials to be at unclear risk of bias. All other included trials were at low risk of other sources of bias.

Effects of interventions {#CD010806-sec2-0010}
------------------------

See: [Table 1](#CD010806-tbl-0001){ref-type="table"}; [Table 2](#CD010806-tbl-0002){ref-type="table"}

See \'Summary of findings\' table 1 ([Table 1](#CD010806-tbl-0001){ref-type="table"}) and \'Summary of findings\' table 2 ([Table 2](#CD010806-tbl-0002){ref-type="table"}). We have presented the findings by intervention type.

### Comparison 1: Group therapy (CBT) versus control {#CD010806-sec3-0026}

See \'Summary of findings\' table 1 ([Table 1](#CD010806-tbl-0001){ref-type="table"}).

Thirteen trials evaluated group therapy sessions based on cognitive behavioural therapy (CBT) techniques. Ten trials were delivered face‐to‐face ([@CD010806-bbs2-0006]; [@CD010806-bbs2-0012]; [@CD010806-bbs2-0005]; [@CD010806-bbs2-0001]; [@CD010806-bbs2-0002]; [@CD010806-bbs2-0003]; [@CD010806-bbs2-0011]; [@CD010806-bbs2-0014]; [@CD010806-bbs2-0013]) and two were delivered by telephone ([@CD010806-bbs2-0009]; [@CD010806-bbs2-0010]). The primary focus of CBT was stress reduction or coping (nine trials), self‐efficacy (one trial), depression (one trial), adherence (one trial), and adherence and depression (one trial). Eight trials described additional relaxation components such as progressive muscle relaxation (PMR) or meditation, four explicitly described methods to facilitate peer/group support, and six described specific educational components. Most sessions lasted between 50 and 135 minutes, were conducted weekly for between eight and 12 weeks, and included between four and 12 participants ([Table 9](#CD010806-tbl-0009){ref-type="table"}).Table 5Description of cognitive‐behavioural interventions**TrialGroup sizeSession duration (mins)Session frequencyInterventionComparisonUnderlying theoryPrimary focusComponentsSkills trainingRelaxation techniquesPeer support^2^Education^2^**[@CD010806-bbs2-0012]6 to 1090Weekly for 8 weeksCognitive‐behaviouralStress managementCognitive restructuring\
coping skillsProgressive muscle relaxation (PMR)/meditation/yogaNot describedNot describedNo intervention ‐ waitlist group[@CD010806-bbs2-0005]4 to 9135Weekly for 10 weeksCognitive‐behaviouralStress managementCognitive restructuring, coping skills, anger management, use of social networkPMR/meditationNot describedNot describedNo intervention ‐ waitlist group[@CD010806-bbs2-0001]4 to 9135Weekly for 10 weeksCognitive‐behaviouralStress managementCognitive restructuring, coping skillsPMR/meditationNot describedMedication adherence1 hour medication adherence training (MAT)[@CD010806-bbs2-0002]4 to 6135Weekly for 10 weeksCognitive‐behaviouralStress managementCognitive restructuring, coping skills, assertiveness, anger management, use of social networkPMR/meditationNot describedNot describedCondensed 1 day CBSM workshop[@CD010806-bbs2-0003]4 to 10120Weekly for 12 weeksCognitive‐behaviouralStress managementCognitive strategiesPMRGroup dynamic exercisesHIV related topicsNo intervention ‐ 30‐minute health check by physician[@CD010806-bbs2-0016]1090Weekly for 15 weeksCognitive theory of stress and copingTraumatic stressCognitive appraisal, coping skills\'relaxation strategies\'Not describedNot describedAttention control ‐ HIV standard therapeutic support group[@CD010806-bbs2-0006]8 to 1090Weekly for 10 weeksCognitive theory of stress and copingCoping/stressAppraising stressors, coping skills, stress management\'relaxation guidance\'Skill building group exercisesPsychoeducation around models of copingNo intervention ‐ waitlist group[@CD010806-bbs2-0009]6 to 890Weekly for 8 weeksTransactional model of stress and copingCopingAppraising stressors, coping skills, use of personal and social resourcesNoNot describedNot describedNo intervention ‐ usual care[@CD010806-bbs2-0010]6 to 81090Weekly for 12 weeksTransactional model of stress and copingCopingAppraising stressors, coping skills, use of personal and social resourcesNoNot describedNot describedNo intervention ‐ individual therapy upon request (ITUR)[@CD010806-bbs2-0011]Not stated120Weekly for 10 weeksCognitive‐behaviouralSelf‐efficacyCognitive restructuring, stress management, coping skills, anger management, use of social network\'relaxation\'Expressive supportive therapyHIV/mental health topicsAttention control group[@CD010806-bbs2-0013]10 to 12120 to 180Weekly for 8 weeksCognitive‐behavioural, social learning theory, and the sustainable livelihoods frameworkDepressionCoping skills, problem solving skills, dealing with stigma, income‐generationNot describedGroup ritualsTriggers, symptoms, and treatment of depression.Active control group[@CD010806-bbs2-0015]Not stated50 minsWeekly for 9 weeksCognitive‐behaviouralAdherence/ depressionCognitive restructuring, problem solving, activity schedulingPMR/diaphragmatic breathingNot describedAdherence, depressionEnhanced treatment as usual (ETAU)[@CD010806-bbs2-0014]1060 minsMonthly for 3 monthsCognitive‐behaviouralAdherenceNot specifically describedNot describedBuddy system to increase social supportKnowledge of HIV and HIV‐related medicationNo intervention ‐ standard care[^8]

Fourteen trials were from high‐income settings (USA, Canada, and Switzerland). Two trials were from low‐ or middle‐income settings: South Africa ([@CD010806-bbs2-0014]), and Uganda ([@CD010806-bbs2-0013]). Five trials were conducted among general populations, three trials with homosexual men, one trial with women from minority groups, one trial with women with an abnormal cervical smear, one trial among prior intravenous drug users, one trial among people with a history of being abused, and one trial among people with adherence problems (see [Table 5](#CD010806-tbl-0005){ref-type="table"}).

#### Depression scores {#CD010806-sec4-0003}

Overall, there was a small reduction in mean depression scores at the end of the group sessions (standardized mean difference (SMD) −0.17, 95% confidence interval (CI) −0.29 to −0.05; 1142 participants, 9 trials; *low certainty evidence*; [Analysis 1.1](#CD010806-fig-00101){ref-type="fig"}), and this appeared to be maintained for up to 15 months after randomization (SMD −0.26, 95% CI −0.42 to −0.10; 1139 participants, 10 trials, *low certainty evidence*; [Analysis 1.1](#CD010806-fig-00101){ref-type="fig"}).

The most commonly used depression score was Beck Depression Inventory (BDI) (used by six trials), which scores depression out of 63. The overall effect was a reduction of around 1.4 points (mean difference (MD) −1.41, 95% CI −2.61 to −0.21; 753 participants, 6 trials, [Analysis 1.2](#CD010806-fig-00102){ref-type="fig"}). See [Table 6](#CD010806-tbl-0006){ref-type="table"} for a description of the different depression scores that the included trials used.

Mean depression scores at baseline were in the depressive range in five trials. Over the duration of these trials, there was a modest improvement in mean score in both the intervention and control groups, but only two trials showed increased benefit with the intervention ([Analysis 1.3](#CD010806-fig-00103){ref-type="fig"}). In the remaining five trials mean depression scores were in the normal range at baseline, and there was a small but consistent reduction in mean score with the intervention ([Analysis 1.5](#CD010806-fig-00105){ref-type="fig"}).

We conducted additional subgrouping by the type of control group used ([Analysis 1.4](#CD010806-fig-00104){ref-type="fig"}), the primary focus of the intervention ([Analysis 1.6](#CD010806-fig-00106){ref-type="fig"}), and gender ([Analysis 1.7](#CD010806-fig-00107){ref-type="fig"}). The most consistent effects on depression were from three trials that focused on stress management interventions (SMD −0.46, 95% CI −0.73 to −0.18; 216 participants, 3 trials).

#### Anxiety scores {#CD010806-sec4-0004}

Four trials assessed measures of anxiety, and overall there was no effect apparent at the end of the group sessions (SMD −0.01, 95% CI −0.25 to 0.22; 420 participants, 3 trials, *low certainty evidence*), or at 12 to 15 months after randomization (SMD −0.12, 95% CI −0.31 to 0.06; 471 participants, 4 trials, *low certainty evidence*; [Analysis 1.8](#CD010806-fig-00108){ref-type="fig"}).

All four trials used different anxiety scales, and only one trial (using the Hospital Anxiety and Depression Scale) reported a statistically significant effect (see [Table 7](#CD010806-tbl-0007){ref-type="table"} and [Analysis 1.9](#CD010806-fig-00109){ref-type="fig"}). This study was conducted in Switzerland among the general population, and baseline and end anxiety scores were in the normal range ([@CD010806-bbs2-0003]). Only the participants recruited by [@CD010806-bbs2-0006] appeared to have substantial anxiety at baseline, and although there was a small improvement in both groups over the course of the trial, there were no differences between groups at any time point.

#### Stress scores {#CD010806-sec4-0005}

Five trials assessed measures of stress, and overall there was no effect apparent at the end of group sessions (SMD −0.06, 95% CI −0.23 to 0.12; four trials, 533 participants, *low certainty evidence*, [Analysis 1.11](#CD010806-fig-00111){ref-type="fig"}), or at the end of follow‐up (SMD −0.04, 95% CI −0.23 to 0.15; five trials, 507 participants, *low certainty evidence*, [Analysis 1.11](#CD010806-fig-00111){ref-type="fig"}). Only [@CD010806-bbs2-0002], which was conducted among HIV‐positive women with a recent abnormal cervical smear, found a statistically significant effect at any time point. For a description of the stress scores used see [Table 8](#CD010806-tbl-0008){ref-type="table"} and [Analysis 1.12](#CD010806-fig-00112){ref-type="fig"}.

#### Coping scores {#CD010806-sec4-0006}

Five trials reported some measure of coping with no effects seen at the end of group therapy (SMD 0.02, 95% CI −0.16 to 0.19; 762 participants, 5 trials; *low certainty evidence*, [Analysis 1.14](#CD010806-fig-00114){ref-type="fig"}), or at the end of follow‐up (SMD 0.04, 95% CI −0.11 to 0.19; 697 participants, 5 trials; *low certainty evidence*; [Analysis 1.14](#CD010806-fig-00114){ref-type="fig"}). In all measures of coping, higher scores reflected increased coping (see [Table 10](#CD010806-tbl-0010){ref-type="table"} and [Analysis 1.15](#CD010806-fig-00115){ref-type="fig"}).Table 6Coping scales reported by trials**ScaleNumber of itemsScore for each item^1^Total scoreInterpretationDescription^2^Trials**Coping Self‐Efficacy Scale (CSES) ([@CD010806-bbs2-0092])260 (cannot do at all) to 10 (certain can do)0 to 260Higher scores indicate better coping skillsParticipants rate the extent to which they believe they could perform behaviours important to adaptive coping[@CD010806-bbs2-0006]; [@CD010806-bbs2-0009]Cognitive Behavioral Self Efficacy (CB‐SE) ([@CD010806-bbs2-0105])70 (not at all) to 4 (all of the time)0 to 28Higher scores indicate higher self‐efficacyParticipants rate their certainty that they could perform certain skills related to AIDS, and antiretroviral medication adherence[@CD010806-bbs2-0011]Dealing with Illness Scale ‐ coping subscale (DIS) ([@CD010806-bbs2-0108])400 (never used) to 3 (regularly used)0 to 120Higher scores reflect more frequent use of the various coping strategies.The DIS is a 40‐item coping subscale modelled on the Revised Ways of Coping Checklist. Participants rate the frequency that thoughts or behaviours have been used to deal with problems and stresses over the past month.[@CD010806-bbs2-0012]\'Avoidant Coping Scale\'\
Created from 23 items taken from \'The ways of Coping Questionnaire\' and \'the Coping with AIDS Scale\' ([@CD010806-bbs2-0016])230 (not at all) to 3 (used a great deal)0 to 69Higher scores reflect more frequent use of coping strategiesParticipants rate how often they have used avoidant strategies for coping[@CD010806-bbs2-0016][^9]

### Comparison 2: Group therapy (mindfulness) versus control {#CD010806-sec3-0027}

Three trials evaluated face‐to‐face group therapy sessions based on mindfulness stress reduction ([@CD010806-bbs2-0004]; [@CD010806-bbs2-0007]; [@CD010806-bbs2-0008]). The interventions included mindfulness meditation, with one intervention including mantram repetition and one described additional educational components. Group sessions lasted between 135 and 180 minutes, and were conducted weekly for eight to 10 weeks, plus one day retreat, The group size was eight to 18 participants across trials (see [Table 11](#CD010806-tbl-0011){ref-type="table"}).Table 7Description of mindfulness interventions**TrialGroup sizeSession duration (mins)Session frequencyInterventionComparisonPrimary focusSecondary componentsRelaxation techniquesPeer supportEducation**[Duncan 2012](Duncan 2012)Not stated150 to 180Weekly for 8 weeks plus 1 day retreatMindfulness‐stress reductionMindfulness meditationNot describedStress physiology and reactivityNo intervention ‐ waitlist group[Gayner 2012](Gayner 2012)14 to 18180Weekly for 8 weeks plus 1 day retreatMindfulness‐stress reductionMindfulness meditationNot describedNot describedNo intervention ‐ treatment as usual (TAU) group offered at end of intervention[@CD010806-bbs2-0004]8 to 1590Weekly for 5 weeks, then 4 automated phone calls, then a final session in week 10Mindfulness‐stress reductionMantram repetitionNot describedNot describedAttention control

All trials were conducted in high‐income settings. One trial was conducted among homosexual men in Canada ([@CD010806-bbs2-0008]), one trial was among men and women experiencing some side effects or distress in the USA ([@CD010806-bbs2-0007]), and the other included trial was among men and women (50%) who were homosexual ([@CD010806-bbs2-0004]) (see [Table 5](#CD010806-tbl-0005){ref-type="table"}).

#### Depression scores {#CD010806-sec4-0007}

Individually, none of these trials reported statistically significant effects on mean depression scores. The pooled effect suggests a modest reduction in mean scores at the end of the group sessions (SMD −0.22, 95% CI −0.48 to 0.04; 242 participants, 3 trials; *very low certainty evidence*, [Analysis 2.1](#CD010806-fig-00201){ref-type="fig"}), and at six months postrandomization (SMD −0.23, 95% CI −0.49 to 0.03; 233 participants, 3 trials;*very low certainty evidence*; [Analysis 2.1](#CD010806-fig-00201){ref-type="fig"}), but the 95% CIs were wide and included no effect.

#### Anxiety scores {#CD010806-sec4-0008}

[@CD010806-bbs2-0004] and [@CD010806-bbs2-0008] measured anxiety scores using different measurement scales. There were no statistically significant differences in the mean scores at the end of the group sessions (SMD −0.23, 95% CI −0.53 to 0.07; 178 participants, 2 trials, *very low certainty evidence*; [Analysis 2.2](#CD010806-fig-00202){ref-type="fig"}), or at six months (SMD −0.16, 95% CI −0.47 to 0.15; 162 participants, 2 trials, *very low certainty evidence*; [Analysis 2.2](#CD010806-fig-00202){ref-type="fig"}).

#### Stress scores {#CD010806-sec4-0009}

[@CD010806-bbs2-0004] and [@CD010806-bbs2-0007] measured stress scores using the perceived stress score, A small statistically significant difference was present at the end of group sessions (MD −2.29, 95% CI −4.46 to −0.11; 139 participants, 2 trials; *very low certainty evidence*), but not at six months postrandomization (MD −2.02, 95% CI −4.23 to 0.19; 137 participants, 2 trials, *very low certainty evidence*; [Analysis 2.3](#CD010806-fig-00203){ref-type="fig"}). The effect size was around 2 points on a 40‐point scale.

Discussion {#CD010806-sec1-0006}
==========

Summary of main results {#CD010806-sec2-0011}
-----------------------

Group‐based psychosocial interventions based on cognitive behavioural therapy (CBT) may have a small effect on measures of depression, and this effect may last for up to 15 months after participation in the group sessions (*low certainty evidence*). Most trials used the Beck Depression Inventory (BDI) which has a maximum score of 63, and the mean score in the intervention groups was around 1.4 points lower at the end of follow‐up. This small benefit was consistent across five trials where participants had a mean depression score in the normal range at baseline, but trials where the mean score was in the depression range at baseline effects were less consistent. Fewer trials reported measures of anxiety (*low certainty evidence*), stress (*low certainty evidence*), and coping (*low certainty evidence*), and there was no clear evidence of effects.

Group‐based interventions based on mindfulness have not demonstrated effects on measures of depression (*very low certainty evidence*), anxiety (*very low certainty evidence*), or stress (*very low certainty evidence*).

Overall completeness and applicability of evidence {#CD010806-sec2-0012}
--------------------------------------------------

Most of the trial interventions were based on cognitive‐behavioural approaches, which were delivered in similar ways (with similar group sizes, similar trained facilitators, and similar numbers of sessions). Most included trials were conducted in high‐income settings (USA, Canada, and Switzerland). Two trials of CBT were conducted in low‐ and middle‐income countries, which is where the prevalence of HIV is highest; over 95% of HIV infections are in low‐ and middle‐income countries, two‐thirds of them in sub‐Saharan Africa ([@CD010806-bbs2-0090]). One trial was conducted among an urban population in Uganda and measures of depression improved significantly in both the intervention and control groups over the course of the study (greater than 10 points on a 20‐point scale) with only small differences between groups (2.5 points). The small effects in the Uganda trial are unlikely to be cost‐effective where resources and trained staff are scarce. The trial conducted among depressed adults on ART in South Africa showed no effects between the two groups for depression.

One of the main aims of this Cochrane Review was to evaluate whether effects seen at the end of group sessions persisted, or were lost, and our findings do seem to suggest that improvements at the end of group session are sustained for up to 15 months. However, as over half the included trials had mean scores at baseline within the normal range (not depressed), the clinical significance of this effect is unclear. In trials that did contain people with measurable depression the effects were inconsistent and there were too few trials to explore why some interventions seemed to have a benefit and some did not.

The included trials used a variety of measurement scales to assess each outcome which made pooling of studies and comparison across population groups difficult.

Quality of the evidence {#CD010806-sec2-0013}
-----------------------

We rated the certainty of the evidence for a small effect on measures of depression with CBT group therapy as \'low\' meaning we can only have low confidence in the observed effect. We downgraded the evidence from high to low due to \'risk of bias\': as most studies were at unclear risk of selection bias and high risk of attrition bias, and due to \'indirectness\' of the evidence (with most trials being from high income settings), and the difficulty in generalising the findings to other settings and population groups. We also rated the evidence of no effect on anxiety, stress, and coping as \'low\' for the same reasons.

For mindfulness‐based group interventions, we rated all outcomes as \'very low\' meaning we are very uncertain about the observed effect. We downgraded the evidence for \'risk of bias\' due to deficiencies in the study methods, \'indirectness\' due to the difficulty generalising the findings to other populations and settings, and \'imprecision\' as the effect is towards benefit but the 95% CI are wide and include no effect.

Potential biases in the review process {#CD010806-sec2-0014}
--------------------------------------

The inclusion criteria of this Cochrane Review may increase the possibility of poor reproducibility due to many subjective decisions regarding which studies and populations to include. We included all HIV‐positive populations (both genders) and we had no exclusion criteria regarding settings when we selected studies for inclusion. However, we minimized this potential bias by including stringent follow‐up time criteria and only RCTS.

We only assessed peer‐reviewed published trials, which may have led to exclusion of trials in grey literature and presented at conferences. Having no knowledge of unpublished studies may have limited the assessment of the strength of the body of evidence in the review. Another limitation is that we only included papers that reported in English, thus disregarding high quality trials that may have been published in other languages.

We selected only trials that used validated scales, which is a strength of the review. We amended specified outcomes by only including psychological outcomes and no longer behavioural outcomes after we realized that there were poor or invalidated assessments for behavioural outcomes in the first set of literature search results (June 2013). Our decision to change specified outcomes after seeing the results for included studies could have lead to biased and misleading interpretation if the importance of the outcome (primary or secondary) is changed on the basis of those results. We have provided transparency in the reporting of changes in outcome specification to reduce this risk of bias.

Even when review authors have a common understanding of the selection criteria, random error or mistakes may result from individual errors in reading and reviewing studies. We reduced this potential bias by ensuring that all review authors read the papers and extracted data independently, and then came to mutual agreements.

We noted issues regarding poor reporting in the papers and we were unable to obtain all relevant data due to the lack of responses from study authors about missing data or clarification of data.

Agreements and disagreements with other studies or reviews {#CD010806-sec2-0015}
----------------------------------------------------------

To our knowledge, no published systematic review has assessed the psychological impact of psychosocial group interventions for HIV positive adults.

The findings of this Cochrane Review are in contrast to a narrative review ([@CD010806-bbs2-0091]), as well as older meta‐analysis syntheses ([@CD010806-bbs2-0096]; [@CD010806-bbs2-0119]), of the effect of various group interventions on outcomes for improved mental health. These report on how stress management and cognitive behavioural interventions and mindfulness‐based interventions are effective in improving various psychological states in people living with HIV. However, [@CD010806-bbs2-0096] did not assess the randomization method, allocation concealment, and blinding used by the trials, thus making data extraction and quality assessment less rigorous. [@CD010806-bbs2-0119]\'s meta‐analytic review of RCTs of stress‐management interventions showed significant overall impact on mental health, whereas [@CD010806-bbs2-0091]\'s narrative critique of the effectiveness of mindfulness based intervention is the only review of the effectiveness of mindfulness‐based interventions on mental health that we found. However, the [@CD010806-bbs2-0091] review is undermined by inclusion of trials that did not fit our stringent inclusion criteria that trials must have had longer than three months follow‐up in order to show sustained effects, and did not include a meta‐analysis. Similar to our Cochrane Review, current published reviews on this subject mainly include trials in high‐income settings, which makes a strong case for high quality research to be funded and motivated for marginalized populations where HIV is most prevalent.

Authors\' conclusions {#CD010806-sec1-0007}
=====================

Group‐based psychosocial interventions may have a small but sustained effect on measures of depression. However, the clinical importance of this is unclear as we only consistently observed the small effect in trials where the mean score of participants in both the intervention and control groups was in the normal range (not depressed) for the duration of the trial.Further trials that include people with signs of depression, stress, or poor coping at baseline will provide evidence of improving psychological adjustment and coping for those who need it most.Further randomized studies should also meet current standards in reporting of methods as outlined in the CONSORT statement and take appropriate steps to reduce the risk of bias.To enable a clear understanding of the results, and facilitate future meta‐analyses, it would also be useful if this research field utilized a common set of outcome scales rather than the ad‐hoc selection that is seen across the included studies.Additionally, evidence is lacking where HIV prevalence is the highest. This indicates a need for strengthening trial research capacity in low‐ and middle‐income settings.
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**Search setCENTRALMEDLINEEmbase**1MeSH descriptor: \[HIV Infections\] explode all trees(HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\])) OR \"sexually transmitted diseases, Viral\"\[MeSH:NoExp\]))\'human immunodeficiency virus infection\'/exp OR \'human immunodeficiency virus\'/exp OR \'human immunodeficiency virus\':ab,ti OR \'human immuno+deficiency virus\':ab,ti OR \'human immunedeficiency virus\':ab,ti OR \'human immune+deficiency virus\':ab,ti OR hiv:ab,ti OR \'hiv‐1\':ab,ti OR \'hiv‐2\':ab,ti OR \'acquired immunodeficiency syndrome\':ab,ti OR \'acquired immuno+deficiency syndrome\':ab,ti OR \'acquired immunedeficiency syndrome\':ab,ti OR \'acquired immune+deficiency syndrome\':ab,ti2MeSH descriptor: \[HIV\] explode all trees(randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])(psychosocial NEXT/1 intervention\*):ab,ti OR \'social support\'/syn OR \'social support\':ab,ti OR (social NEXT/1 network\*):ab,ti OR (support NEXT/1 system\*):ab,ti OR \'self help\'/syn OR (\'self‐help\' NEXT/1 group\*):ab,ti OR (support NEXT/1 group\*):ab,ti OR \'educational therapy\':ab,ti OR \'psychotherapy\'/syn OR psychotherapy:ab,ti OR \'group therapy\'/syn OR \'group therapy\':ab,ti OR \'behavior therapy\':ab,ti OR \'behaviour therapy\':ab,ti OR \'family therapy\':ab,ti OR \'group interventions\':ab,ti OR \'cognitive therapy\':ab,ti OR \'cognition therapy\':ab,ti OR (psychological NEXT/1 adjustment\*):ab,ti OR \'psychological adaptation\':ab,ti OR (adaptive NEXT/1 behavior\*):ab,ti OR (adaptive NEXT/1 behaviour\*):ab,ti OR (coping NEXT/1 behavio\*):ab,ti OR (coping NEXT/1 intervention\*):ab,ti OR (coping NEXT/1 strateg\*):ab,ti OR (coping NEXT/1 skill\*):ab,ti3hiv or hiv‐1\* or hiv‐2\* or hiv1 or hiv2 or HIV INFECT\* or HUMAN IMMUNODEFICIENCY VIRUS or HUMAN IMMUNEDEFICIENCY VIRUS or HUMAN IMMUNE‐DEFICIENCY VIRUS or HUMAN IMMUNO‐DEFICIENCY VIRUS or HUMAN IMMUN\* DEFICIENCY VIRUS or ACQUIRED IMMUNODEFICIENCY SYNDROME or ACQUIRED IMMUNEDEFICIENCY SYNDROME or ACQUIRED IMMUNO‐DEFICIENCY SYNDROME or ACQUIRED IMMUNE‐DEFICIENCY SYNDROME or ACQUIRED IMMUN\* DEFICIENCY SYNDROME(psychosocial intervention\*\[tiab\] OR social support\[mh\] OR social network\*\[tiab\] OR social support\[tiab\] OR support system\[tiab\] OR support systems\[tiab\] OR self‐help groups\[mh\] OR self‐help group\[tiab\] OR self‐help groups\[tiab\] OR support group\[tiab\] OR support groups\[tiab\] OR educational therapy\[tiab\] OR psychotherapy\[mh\] OR psychotherapy\[tiab\] OR behavior therapy\[tiab\] OR behaviour therapy\[tiab\] OR family therapy\[tiab\] OR group therapy\[tiab\] OR group interventions\[tiab\] OR cognitive therapy\[tiab\] OR cognition therapy\[tiab\] OR adaptation, psychological\[mh\] OR psychological adjustment\[tiab\] OR psychological adjustments\[tiab\] OR psychological adaptation\[tiab\] OR adaptive behavior\[tiab\] OR adaptive behaviors\[tiab\] OR adaptive behaviour\[tiab\] OR adaptive behaviours\[tiab\] OR coping behavio\* \[tiab\] OR coping intervention\*\[tiab\] OR coping strateg\*\[tiab\] OR coping skill\*\[tiab\])\#1 AND \#24MeSH descriptor: \[Lymphoma, AIDS‐Related\] this term only(\#1 AND \#2 AND \#3)\'randomized controlled trial\'/de OR \'randomized controlled trial\' OR random\*:ab,ti OR trial:ti OR allocat\*:ab,ti OR factorial\*:ab,ti OR placebo\*:ab,ti OR assign\*:ab,ti OR volunteer\*:ab,ti OR \'crossover procedure\'/de OR \'crossover procedure\' OR \'double‐blind procedure\'/de OR \'double‐blind procedure\' OR \'single‐blind procedure\'/de OR \'single‐blind procedure\' OR (doubl\* NEAR/3 blind\*):ab,ti OR (singl\*:ab,ti AND blind\*:ab,ti) OR crossover\*:ab,ti OR cross+over\*:ab,ti OR (cross NEXT/1 over\*):ab,ti5MeSH descriptor: \[Sexually Transmitted Diseases, Viral\] this term only\[DW1\]Search (((\#1 AND \#2 AND \#3)))\'animal\'/de OR \'animal experiment\'/de OR \'invertebrate\'/de OR \'animal tissue\'/de OR \'animal cell\'/de OR \'nonhuman\'/de6\#1 or \#2 or \#3 or \#4 or \#5---\'human\'/de OR \'normal human\'/de OR \'human cell\'/de7MeSH descriptor: \[Social Support\] explode all trees---\#5 AND \#68MeSH descriptor: \[Self‐Help Groups\] explode all trees---\#5 NOT \#79MeSH descriptor: \[Psychotherapy\] explode all trees---\#4 NOT \#810MeSH descriptor: \[Adaptation, Psychological\] explode all trees---\#3 AND \#911\"psychosocial intervention\*\":ti,ab,kw or \"social support\":ti,ab,kw or (social next network\*):ti,ab,kw or (support next system\*):ti,ab,kw or (self‐help next group\*):ti,ab,kw or (support next group\*):ti,ab,kw or educational therapy:ti,ab,kw or psychotherapy:ti,ab,kw or \"behavior therapy\":ti,ab,kw or \"behaviour therapy\":ti,ab,kw or \"family therapy\":ti,ab,kw or \"group therapy\":ti,ab,kw or \"group interventions\":ti,ab,kw or \"cognitive therapy\":ti,ab,kw or \"cognition therapy\":ti,ab,kw or (psychological next adjustment\*):ti,ab,kw or \"psychological adaptation\":ti,ab,kw or \"adaptive behavior\":ti,ab,kw or \"adaptive behaviour\":ti,ab,kw or \"coping behavior\":ti,ab,kw or \"coping behaviour\":ti,ab,kw or \"coping skills\":ti,ab,kw or \"coping strategies\":ti,ab,kw (Word variations have been searched)---\#3 AND \#912\#7 or \#8 or \#9 or \#10 or \#11------13\#6 and \#12------

Search strategy: (psychosocial OR \"social support\" OR \"coping skills\" OR \"self‐help groups\" OR \"cognitive therapy\") AND hiv \| Interventional Studies \| received from 01/01/1996 to 03/14/2016

**Authors and yearSample size and population characteristicsTrialsettingTrialdesignTrialobjectivesMethodological criteriaEligibility criteriaIntervention componentsOutcome measuresResults and effect size**

Comparison 1Group therapy (CBT) versus controlOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Depression scores](#CD010806-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Group therapy (CBT) versus control, Outcome 1 Depression scores.10Std. Mean Difference (IV, Random, 95% CI)Subtotals only1.1 Baseline mean scores101600Std. Mean Difference (IV, Random, 95% CI)0.05 \[‐0.05, 0.15\]1.2 Mean score at end of group sessions (10 to 12 weeks after randomization)91142Std. Mean Difference (IV, Random, 95% CI)‐0.17 \[‐0.29, ‐0.05\]1.3 Mean score at longest follow‐up (6 to 15 months after randomization)101139Std. Mean Difference (IV, Random, 95% CI)‐0.26 \[‐0.42, ‐0.10\][2 Depression scores at longest follow‐up; subgrouped by depression score used](#CD010806-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Group therapy (CBT) versus control, Outcome 2 Depression scores at longest follow‐up; subgrouped by depression score used.10Mean Difference (IV, Random, 95% CI)Subtotals only2.1 Beck depression inventory (score out of 63)6753Mean Difference (IV, Random, 95% CI)‐1.41 \[‐2.61, ‐0.21\]2.2 Hospital Anxiety and Depression score (score out of 21)171Mean Difference (IV, Random, 95% CI)‐2.12 \[‐3.90, ‐0.34\]2.3 Geriatric depression score (score out of 30)1160Mean Difference (IV, Random, 95% CI)‐1.48 \[‐2.83, ‐0.13\]2.4 Centre for Epidemiological Studies (score out of 60)170Mean Difference (IV, Random, 95% CI)0.30 \[‐4.03, 4.63\]2.5 Self‐reported questionnaire (score out of 20)185Mean Difference (IV, Random, 95% CI)‐2.5 \[‐3.91, ‐1.09\]2.6 Profile of mood states (depression) (score out of 60)1101Mean Difference (IV, Random, 95% CI)‐4.30 \[‐10.47, 1.87\]2.7 Montgomery‐Asberg Depression Rating Scale (score out of 60)166Mean Difference (IV, Random, 95% CI)‐4.72 \[‐9.67, 0.23\][3 Depression scores (trials with mean scores in the range of depression at baseline)](#CD010806-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Group therapy (CBT) versus control, Outcome 3 Depression scores (trials with mean scores in the range of depression at baseline).5Std. Mean Difference (IV, Random, 95% CI)Subtotals only3.1 Baseline mean scores5790Std. Mean Difference (IV, Random, 95% CI)0.04 \[‐0.10, 0.18\]3.2 Mean score at longest follow‐up5628Std. Mean Difference (IV, Random, 95% CI)‐0.20 \[‐0.46, 0.06\][4 Depression scores at longest follow‐up; subgrouped by control](#CD010806-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Group therapy (CBT) versus control, Outcome 4 Depression scores at longest follow‐up; subgrouped by control.10Std. Mean Difference (IV, Random, 95% CI)Subtotals only4.1 Standard care ± a minimal intervention (\< 1 day)6595Std. Mean Difference (IV, Random, 95% CI)‐0.24 \[‐0.45, ‐0.04\]4.2 Alternative group sessions3300Std. Mean Difference (IV, Random, 95% CI)‐0.25 \[‐0.71, 0.22\]4.3 Individual therapy2389Std. Mean Difference (IV, Random, 95% CI)‐0.22 \[‐0.42, ‐0.01\][5 Depression scores (trials with mean scores in the normal range at baseline)](#CD010806-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Group therapy (CBT) versus control, Outcome 5 Depression scores (trials with mean scores in the normal range at baseline).5Std. Mean Difference (IV, Random, 95% CI)Subtotals only5.1 Baseline mean scores5810Std. Mean Difference (IV, Random, 95% CI)0.10 \[‐0.11, 0.30\]5.2 Mean score at longest follow‐up (6 to 15 months after randomization)5511Std. Mean Difference (IV, Random, 95% CI)‐0.30 \[‐0.48, ‐0.13\][6 Depression scores at longest follow‐up; subgrouped by primary focus of intervention](#CD010806-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Group therapy (CBT) versus control, Outcome 6 Depression scores at longest follow‐up; subgrouped by primary focus of intervention.10Std. Mean Difference (IV, Random, 95% CI)Subtotals only6.1 Stress management3216Std. Mean Difference (IV, Random, 95% CI)‐0.46 \[‐0.73, ‐0.18\]6.2 Coping3396Std. Mean Difference (IV, Random, 95% CI)‐0.14 \[‐0.37, 0.08\]6.3 Self‐efficacy1229Std. Mean Difference (IV, Random, 95% CI)‐0.13 \[‐0.39, 0.13\]6.4 Depression185Std. Mean Difference (IV, Random, 95% CI)‐0.75 \[‐1.19, ‐0.30\]6.5 Adherence and depression166Std. Mean Difference (IV, Random, 95% CI)‐0.43 \[‐0.92, 0.06\]6.6 Adherence1147Std. Mean Difference (IV, Random, 95% CI)0.03 \[‐0.30, 0.35\][7 Depression scores at longest follow‐up; subgrouped by gender](#CD010806-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Group therapy (CBT) versus control, Outcome 7 Depression scores at longest follow‐up; subgrouped by gender.101139Std. Mean Difference (IV, Random, 95% CI)‐0.26 \[‐0.42, ‐0.10\]7.1 Men only3215Std. Mean Difference (IV, Random, 95% CI)‐0.26 \[‐0.55, 0.04\]7.2 Women only1229Std. Mean Difference (IV, Random, 95% CI)‐0.13 \[‐0.39, 0.13\]7.3 Both men and women6695Std. Mean Difference (IV, Random, 95% CI)‐0.31 \[‐0.55, ‐0.07\][8 Anxiety scores](#CD010806-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Group therapy (CBT) versus control, Outcome 8 Anxiety scores.4Std. Mean Difference (IV, Random, 95% CI)Subtotals only8.1 Baseline mean scores4697Std. Mean Difference (IV, Random, 95% CI)0.11 \[‐0.05, 0.27\]8.2 Mean score at end of group sessions (10 to 12 weeks after randomization)3420Std. Mean Difference (IV, Random, 95% CI)‐0.01 \[‐0.25, 0.22\]8.3 Mean score at longest follow‐up (12 to 15 months after randomization)4471Std. Mean Difference (IV, Random, 95% CI)‐0.12 \[‐0.31, 0.06\][9 Anxiety scores: at longest follow‐up; subgrouped by anxiety scale used](#CD010806-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Group therapy (CBT) versus control, Outcome 9 Anxiety scores: at longest follow‐up; subgrouped by anxiety scale used.4Mean Difference (IV, Random, 95% CI)Subtotals only9.1 State trait anxiety inventory (score between 20 and 80)170Mean Difference (IV, Random, 95% CI)‐0.80 \[‐6.06, 4.46\]9.2 Modified State Trait Anxiety Inventory (score between 10 and 40)1229Mean Difference (IV, Random, 95% CI)‐0.61 \[‐2.09, 0.87\]9.3 Hospital Anxety and Depression Scale (score out of 21)171Mean Difference (IV, Random, 95% CI)‐2.4 \[‐4.92, 0.12\]9.4 Profile of Mood States (score out of 36)1101Mean Difference (IV, Random, 95% CI)0.20 \[‐2.64, 3.04\][10 Anxiety scores: at longest follow‐up; subgrouped by control](#CD010806-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Group therapy (CBT) versus control, Outcome 10 Anxiety scores: at longest follow‐up; subgrouped by control.4Mean Difference (IV, Random, 95% CI)Subtotals only10.1 Standard care ± a minimal intervention (\< 1 day)2172Mean Difference (IV, Random, 95% CI)‐1.18 \[‐3.73, 1.36\]10.2 Alternative group therapy170Mean Difference (IV, Random, 95% CI)‐0.80 \[‐6.06, 4.46\]10.3 Individual therapy1229Mean Difference (IV, Random, 95% CI)‐0.61 \[‐2.09, 0.87\][11 Stress scores](#CD010806-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Group therapy (CBT) versus control, Outcome 11 Stress scores.5Std. Mean Difference (IV, Random, 95% CI)Subtotals only11.1 Baseline mean scores5695Std. Mean Difference (IV, Random, 95% CI)0.12 \[‐0.03, 0.27\]11.2 Mean score at end of group sessions4533Std. Mean Difference (IV, Random, 95% CI)‐0.06 \[‐0.23, 0.12\]11.3 Mean score at longest follow‐up5507Std. Mean Difference (IV, Random, 95% CI)‐0.04 \[‐0.23, 0.15\][12 Stress scores at longest follow‐up; subgrouped by stress score used](#CD010806-fig-00112){ref-type="fig"}Analysis 1.12Comparison 1 Group therapy (CBT) versus control, Outcome 12 Stress scores at longest follow‐up; subgrouped by stress score used.5Mean Difference (IV, Random, 95% CI)Subtotals only12.1 Perceived stress score (score out of 40)170Mean Difference (IV, Random, 95% CI)‐0.70 \[‐3.77, 2.37\]12.2 Dealing with illness scale169Mean Difference (IV, Random, 95% CI)‐1.80 \[‐7.62, 4.02\]12.3 HIV‐related life‐stressor burden score (score out of 5)1166Mean Difference (IV, Random, 95% CI)0.08 \[‐0.06, 0.22\]12.4 Life experiences survey (score out of 3)139Mean Difference (IV, Random, 95% CI)‐1.36 \[‐3.00, 0.28\]12.5 Impact of event scale (score out of 75)2232Mean Difference (IV, Random, 95% CI)‐1.33 \[‐3.60, 0.95\][13 Stress scores at longest follow‐up; subgrouped by control](#CD010806-fig-00113){ref-type="fig"}Analysis 1.13Comparison 1 Group therapy (CBT) versus control, Outcome 13 Stress scores at longest follow‐up; subgrouped by control.5Mean Difference (IV, Random, 95% CI)Subtotals only13.1 Standard care ± a minimal intervention (\< 1 day)3274Mean Difference (IV, Random, 95% CI)‐0.37 \[‐1.46, 0.71\]13.2 Alternative group therapy4454Mean Difference (IV, Random, 95% CI)0.09 \[‐0.05, 0.22\]13.3 Individual therapy00Mean Difference (IV, Random, 95% CI)0.0 \[0.0, 0.0\][14 Coping scores](#CD010806-fig-00114){ref-type="fig"}Analysis 1.14Comparison 1 Group therapy (CBT) versus control, Outcome 14 Coping scores.5Std. Mean Difference (IV, Random, 95% CI)Subtotals only14.1 Baseline mean scores51022Std. Mean Difference (IV, Random, 95% CI)0.01 \[‐0.11, 0.14\]14.2 Mean score at end of group sessions5762Std. Mean Difference (IV, Random, 95% CI)0.02 \[‐0.16, 0.19\]14.3 Mean score at longest follow‐up (6 months after randomization)5697Std. Mean Difference (IV, Random, 95% CI)0.04 \[‐0.11, 0.19\][15 Coping scores at longest follow‐up; subgrouped by coping score used](#CD010806-fig-00115){ref-type="fig"}Analysis 1.15Comparison 1 Group therapy (CBT) versus control, Outcome 15 Coping scores at longest follow‐up; subgrouped by coping score used.5Mean Difference (IV, Random, 95% CI)Subtotals only15.1 Dealing with illness: coping subscale (score out of 120)169Mean Difference (IV, Random, 95% CI)1.90 \[‐1.79, 5.59\]15.2 Cognitive behavioural self‐efficacy scale (score out of 28)1229Mean Difference (IV, Random, 95% CI)‐0.16 \[‐1.29, 0.97\]15.3 Coping self‐efficacy scale (score out of 260)2236Mean Difference (IV, Random, 95% CI)1.76 \[‐6.53, 10.05\]15.4 Avoidant coping scale (score out of 69)1163Mean Difference (IV, Random, 95% CI)‐1.70 \[‐5.26, 1.86\][16 Coping scores at longest follow‐up; subgrouped by control](#CD010806-fig-00116){ref-type="fig"}Analysis 1.16Comparison 1 Group therapy (CBT) versus control, Outcome 16 Coping scores at longest follow‐up; subgrouped by control.5Mean Difference (IV, Random, 95% CI)Subtotals only16.1 Standard care ± a minimal intervention (\< 1 day)2235Mean Difference (IV, Random, 95% CI)0.19 \[‐0.21, 0.59\]16.2 Alternative group therapy4454Mean Difference (IV, Random, 95% CI)‐0.25 \[‐0.67, 0.17\]16.3 Individual therapy1229Mean Difference (IV, Random, 95% CI)‐0.16 \[‐1.29, 0.97\]

Comparison 2Group therapy (mindfulness) versus controlOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Depression scores](#CD010806-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Group therapy (mindfulness) versus control, Outcome 1 Depression scores.3Std. Mean Difference (IV, Random, 95% CI)Subtotals only1.1 Baseline mean scores3286Std. Mean Difference (IV, Random, 95% CI)‐0.11 \[‐0.35, 0.12\]1.2 Mean scores at end of group sessions (8 weeks after randomization)3242Std. Mean Difference (IV, Random, 95% CI)‐0.22 \[‐0.48, 0.04\]1.3 Mean score at longest follow‐up3233Std. Mean Difference (IV, Random, 95% CI)‐0.23 \[‐0.49, 0.03\][2 Anxiety scores](#CD010806-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Group therapy (mindfulness) versus control, Outcome 2 Anxiety scores.2Std. Mean Difference (IV, Random, 95% CI)Subtotals only2.1 Baseline mean scores2210Std. Mean Difference (IV, Random, 95% CI)‐0.01 \[‐0.29, 0.27\]2.2 Mean scores at end of group sessions (8 weeks after randomization)2178Std. Mean Difference (IV, Random, 95% CI)‐0.23 \[‐0.53, 0.07\]2.3 Mean score at longest follow‐up2162Std. Mean Difference (IV, Random, 95% CI)‐0.16 \[‐0.47, 0.15\][3 Stress scores](#CD010806-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Group therapy (mindfulness) versus control, Outcome 3 Stress scores.2Mean Difference (IV, Random, 95% CI)Subtotals only3.1 Baseline mean scores2169Mean Difference (IV, Random, 95% CI)‐1.02 \[‐3.50, 1.46\]3.2 Mean scores at end of treatment2139Mean Difference (IV, Random, 95% CI)‐2.29 \[‐4.46, ‐0.11\]3.3 Mean score at longest follow‐up2137Mean Difference (IV, Random, 95% CI)‐2.02 \[‐4.23, 0.19\]

We excluded behavioural outcomes.

We only included the outcomes for meta‐analysis if the trials measured them for at least three months post‐intervention.

We changed the overall outcome of effectiveness to \'psychological well‐being\' instead of \'Quality of Life\' (QOL) as QOL was too broad.

Characteristics of included studies \[ordered by study ID\] {#CD010806-sec2-0021}
===========================================================

[@CD010806-bbs2-0001]Methods**Trial design:** 2‐arm randomized controlled trial (RCT)\
**Follow‐up:** 3, 9, and 15 months follow up\
**Loss to follow‐up:** 22 in treatment group, 23 in control groupParticipants**Population:** 130 HIV‐positive homosexual men receiving highly active antiretroviral therapy (HAART); intervention = 76, control = 54\
**Inclusion criteria:** 18 to 65 years old, no changes in their HAART regime during past month\
**Exclusion criteria:** prescribed medications with immunomodulatory effects, history of chemotherapy or whole‐body radiation for cancer that was not AIDS‐related, history of chronic illness associated with permanent changes in immune systemInterventions**Intervention:** N = 76. Cognitive Behavioural Stress Management (CBSM): focused on eliciting participant experiences with adherence and medication side effects using cognitive restructuring exercises, managing stressors related to adherence, using productive coping responses.\
Group size: 2 to 9.Facilitators: postdoctoral fellows and advanced clinical health psychology graduate students.Session duration: 135 mins (45 mins relaxation component and 90 mins stress management component).Session frequency: 10 weekly sessions.Additional components: relaxation including progressive muscle relaxation (PMR), autogenic training, meditation and deep breathing: participants were asked to practice these between sessions. + Medication adherence training\
**Control:** N = 54. Medication adherence training (MAT): aimed to increase knowledge about HIV and HAART, including how medications work, why they must be taken on time and at the proper dose, and how to recognize possible side effects\
All participants received MAT from a licensed clinical pharmacist in a 1‐hr session at baseline as well as two 30‐min maintenance sessions at 3 months and 9 months postrandomization, respectively.Outcomes**Included in this review**\
Depression by Becks Depression Inventory (BDI) and Profile Of Moods Scale ‐ Depression (POMS‐D).Anxiety by Profile Of Moods Scale ‐ Anxiety (POMS‐A).\
**Not included in this review**\
Immunological outcomes: viral load and CD4.Adherence by Medication Event Monitoring System (MEMS).NotesUsed 2 scales to measure depression POMS‐D and BDI; we chose BDI\
**Setting:** not reported\
**Country:** USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"Participants identification numbers were drawn randomly from a box for assignment to trial conditions.\"Allocation concealment (selection bias)Unclear riskQuote: \"Randomization procedures were conducted by a master's level project manager and overseen by the principal investigator. Participants identification numbers were drawn randomly from a box for assignment to trial conditions.\" No further details.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLoss to follow‐up: 19.7% intervention group versus 25.9% control. Intention‐to‐treat (ITT) analysis done.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0002]Methods**Trial design:** 2‐arm RCT\
**Follow‐up:** 9‐month follow‐up\
**Loss to follow‐up:** Cognitive Behavioral Stess Management (CBSM) group: 47% completed follow‐up; control participants: 69% completed follow‐upParticipants**Population:** 39 HIV‐positive African American, Hispanic, or Caribbean women. Intervention = 21, control = 18.\
**Inclusion criteria:** HIV‐positive women aged 18 to 60 years old; at least 2 Papanicolaou smears indicating low grade squamous intraepithelial lesions (LSIL) or al least 2 cervical biopsies indication CIN 1 (mild or grade 1 neoplasia) in the 2 years prior to trial entry; fluency in spoken English.\
**Exclusion criteria:** no exclusion criteria were listed.Interventions**Treatment:** N = 21. Cognitive behavioural training (CBT) that increased awareness of the effects of stress, identifying and reframing automatic thoughts, improving productive coping skills, anger management, assertiveness training, productive use of one\'s social network, and safer sex negotiation.\
Group size: 4 to 6.Facilitators: doctoral trainees, postdoctoral fellows, and licensed psychologists.Session duration:135 mins (45 mins relaxation training and 90 mins of cognitive behavioural training).Session frequency: 10 weekly sessions.Additional components: weekly homework was assigned, including stress monitoring and relaxation practice.\
**Control:** N = 18. 5‐hour 1‐day CBSM workshop with four 20‐minute relaxation modules, four 40‐minute CBSM modules, and two 30‐minute breaks.Outcomes**Included in this review**\
Life Stress measured using 10‐item abbreviated form of Life Experiences Survey (LES; Sarason, Johnson & Siegel 1978)\
**Not included in this review**\
CD4 and plasma HIV viral load.Cervical intraepithelial neoplasia (CIN).Notes[@CD010806-bbs2-0039] did secondary analysis on psychological well‐being but only used a subset of Beck Depression Inventory (BDI)\
**Setting:** not reported\
**Country:** USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote: \"randomly assigned to either the 10‐week CBSM group intervention or the one‐day CBSM workshop at a 2:1 ratio (experimental:control)\". No further details.Allocation concealment (selection bias)Unclear riskQuote: \"Participants and assessors were blinded to experimental condition during completion of all study entry procedures\". No further details.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLoss to follow‐up: 43.2% intervention group versus 21.7% control. Trial authors conducted an ITT analysis.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0003]Methods**Trial design:** 2‐arm RCT\
**Follow‐up:** 12 months\
**Loss to follow‐up:** intervention loss n = 2; treatment loss n = 4Participants**Population:** 104 HIV‐positive people taking combination antiretroviral therapy (ART), intervention = 53, control = 51.\
**Inclusion criteria:** adults between 18 to 65 years, German speaking, received combination Antiretroviral Therapy (cART) within the 3 months prior to screening, had a CD4 lymphocyte count \> 100 cells/µL and no opportunistic infection at baseline.\
**Exclusion criteria:** received psychotherapy in past 3 months, intravenous drug users or on stable methadone maintenance, diagnosis of psychiatric disorder as determined by standardized interview.Interventions**Treatment:** N = 53. Psychoeducation, group dynamics exercises, homework, cognitive strategies, and PMR\
Group size: 4 to 10.Facilitators: cognitive behavioural psychotherapist and one psychotherapist trainee.Session duration: 120 minutes.Session frequency: 12 weekly sessions.\
**Control:** N = 51. 30‐minute health check by physician.Outcomes**Included in review**\
Anxiety and Depression by HADS.\
**Not included in review**\
CD4 lymphocyte cell count and HIV‐1 RN.Adherence to therapy (SMAQ).Physical and Mental Health (MOS‐HIV).NotesEthics approval.\
**Setting:** outpatient clinics\
**Country:** Switzerland***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"Allocation sequences included randomly permuted block sizes of two and four and were generated using the computer program RANCODE V3.0\".Allocation concealment (selection bias)Low riskQuote: \"Individual assignment codes were properly concealed between black sheets, stored in sequentially numbered envelopes and opened in the presence of study participants\".Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 37.7% intervention group versus 25.5% control group.Trial authors conducted an ITT analysis.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0004]Methods**Trial design:** RCT 2 group by 4 time repeated measures design\
**Follow‐up:** baseline, 10 weeks, 3 months follow‐up, 22 weeks post follow‐up\
**Loss to follow‐up:** 71% completed all trial pointsParticipants**Population:** 93 HIV‐positive adults, intervention = 46, control = 47\
**Inclusion criteria:** HIV‐positive for ≥ 6 months; 18 to 65 years old; no drug or substance abuse for ≥ 6 months; able to read, write, and comprehend English\
**Exclusion criteria:** Trial authors did not list any exclusion criteria**.**Interventions**Treatment:** N = 46. Information on choosing and using a mantram, attention to mindfulness, phone calls to encourage mantram practice.\
Group size: 8 to 15.Facilitators: led by the same 2 Masters\' prepared psychiatric mental health nurses.Session duration:135 mins (45 mins relaxation training and 90 mins of cognitive behavioural training).Session frequency: 10 weekly sessions: 5 x 90 min weekly sessions, followed by 4 weekly automated phone calls from facilitators and a final session in week 10.\
**Control:** N = 47. Videotapes on HIV topics including medications, treatment issues, wasting syndrome, and nutrition. Attention control group the same.Outcomes**Included in review**\
Stress using the Perceived Stress Scale (PSS).Anxiety using the Spielberger Trait‐Anxiety Inventory (STAI).Depression using the Centre for Epidemiological Studies‐Depression Scale (CES‐D).\
**Not included in review**\
Quality of Life assessed with the Overall‐General Activities sub‐scale from the Quality of Life Enjoyment and Satisfaction Questionnaire.Anger using the Spielberger Trait‐Anger Inventory (STAI).Notes50% homosexual participants\
**Setting:** not reported\
**Country:** USA\
University Institutional Review Board approval***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"Random assignment was done by the project coordinator using a table of random numbers and stratifying on CD4 count\".Allocation concealment (selection bias)Unclear riskTrial authors did not describe selection bias.Blinding of participants and personnel (performance bias) AnxietyUnclear riskTrial authors conducted an ITT analysis.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 30.4% intervention group versus 27.7% control group.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasUnclear riskGroups differed on 4 baseline variables; \"baseline imbalance\".[@CD010806-bbs2-0005]Methods**Trial design:** 2‐arm RCT\
**Follow‐up:** pre, post, 6 months, and 12 months\
**Loss to follow‐up:** 50% followed up in intervention and 47% in control.Participants**Population:** 129 HIV seropositive homosexual men. Intervention = 31, control = 18\
**Inclusion criteria:** have at least 1 non‐AIDS HIV‐related symptom occurring within 3 years of trial entry of laboratory signs of mildly progressed HIV infection, have at least an 8th grade education and ability to read and write in fluent English, CD4 counts \> 200 cells/mm³, those on AZT or ART had to have maintained current dosage without change in regimen for at least 2 months before trial entry, those concurrently engaged in psychotherapy or support groups were asked not to change their involvement during the trial\
**Exclusion criteria:** individuals with AIDS symptomology, a prior diagnosis of AIDS (CD4 count \< 200 cells/mm³), those who had been hospitalized in previous 3 months, those who had a chronic immune system‐related physical condition other than HIV and regular use of medications (other than ARVs) with substantial known effects on the endocrine or immune systems, those with psychiatric or neuropsychological conditions, alcohol or substance abuse dependency, or and major psychiatric and personality disorder, who were cognitively impaired, patients with concurrent clinical levels of depression, individuals who had been bereaved of a significant other within the previous 6 months, risk factors for HIV transmission other than sexual orientation (for example, past or present intravenous drug use, blood transfusion), initiating a new psychotherapy or exercise training programme in past 3 monthsInterventions**Treatment:** N = 31. CBSM (GET SMART) included increasing awareness of physiological effects of stress, cognitive behavioural theory of stress and emotions, identification of cognitive distortions and automatic thoughts, rational thought replacement, coping skills training, assertiveness training, anger management, and identification and use of social supports. Homework was assigned and participants were taught a variety of relaxation techniques including PMR, autogenic training, meditation and breathing exercises\
Group size: 4 to 9 men.Facilitators: 2 advanced clinical‐health psychology graduate students.Session duration: 135‐minute group sessions (90‐minute stress management and 45‐minute relaxation) and were asked to complete relaxation exercises twice daily between sessions.Session frequency: 10 weekly sessions.\
**Control:** N = 18. Waitlist, 2 weeks post treatment they were offered a 1 day seminar consisting of condensed CBSM componentsOutcomes**Included in review**\
Depression by BDI.\
**Not included in review**\
Mood by Profile of Mood States (POMS‐TMD).Social Support by Social Provisions Scale (SPS).CD4 by blood sample.Herpes Virus by IgG antibodies.DHEA‐S and cortisol.Notes**Setting:** not reported\
**Country:** USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors described the trial as \"randomized\" but did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection biases, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 66.3% intervention group versus 65.2% control group.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0006]Methods**Trial design:** 3‐arm RCT\
**Follow‐up:** 6 and 12 months\
**Loss to follow‐up:** 86% retainedParticipants**Population:** 149 HIV‐positive men who have sex with men (MSM) and who have depression\
**Inclusion criteria:** (1) self‐identified as homosexual or bisexual, (2) 21 to 60 years of age, (3) self‐reported CD4 levels between 200 and 700 cells/mm³\
**Exclusion criteria:** (1) individuals with major depressive or psychotic disorders, (2) history of drug or alcohol dependency in past year, (3) currently in psychotherapy, (4) using psychoactive medicationInterventions**Treatment:** N = 54. Coping Effectiveness Training (CET) comprising psychoeducation: appraisal of stressful situations, problem‐focused and emotion‐focused coping, use of social support; skills‐building group activities, relaxation guidance.\
Group size: 8 to 10.Facilitators: co‐leaders with graduate experience in social work and clinical psychology or community‐based HIV services.Session duration: 90 minutes.Session frequency: 10 weekly plus 6 maintenance sessions.Additional components: a day‐long retreat and take home activities.\
**Control:** N = 51. HIV‐Informational Control comprising Didactic information on HIV‐related topics and resources, workbooks, fact sheets, and reading material.\
10 weekly 90‐minute group sessions of 8 to 10 men plus 6 maintenance sessions\
**Waiting list**: N = 44. Waiting list controlOutcomes**Included in review**\
Depression by CES‐D.Stress by PSS.Anxiety by STAI.\
**Not included in review**\
Burnout (own scale developed).Negative Morale and Positive morale (Affect Balance Scale).\
**Mediating variables**\
Coping self‐efficacy.Social support.Optimism.Positive state of mind.Notes**Setting:** not reported\
**Country:** San Francisco, USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors described the trial as \"randomized\" but did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLoss to follow‐up: 33.3% intervention versus 33.3% control.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0007]Methods**Trial design:** 2‐arm RCT\
**Follow‐up:** baseline, 3 month and 6 month follow‐up\
**Loss to follow‐up:** 93% 6‐month follow‐upParticipants**Population:** 76 participants actively taking ART, intervention = 40, control = 36\
**Inclusion criteria:** (1) documentation of HIV test results, (2) currently taking a recognized ART regimen and (3) reporting a side effect bother in last 30 days of 8 or a bother on the side effect and symptom distress scale.\
**Exclusion criteria:** (1) if enrolled in another behavioural coping or HIV adherence intervention research trial or MBSRInterventions**Treatment:** N = 40. Mindfulness‐based stress reduction consisting of daily homework, sitting meditation with mindfulness of breath, thoughts, and emotions, including deliberate awareness of routine activities such as eating and interpersonal communication, and yoga postures\
Group size: 2 to 9.Facilitators: course instructor was an experienced MBSR teacher with a personal mindfulness meditation practice who had undergone formal training in the delivery of MBSR.Session duration: 2.5 to 3 hours.Session frequency: 8‐weekly sessions plus 1 day retreat.Additional components: In addition to teaching mindfulness practices, the course includes didactic presentations that include information on stress physiology and stress reactivity. The course also addresses the effects of perception, appraisal,and attitude on health habits and behavior and on interpersonal communication.\
**Control:** N = 36. Waitlist control group offered the MBSR subsequent to 6 month follow‐upOutcomes**Included in the review**\
Depression by BDI.Stress by PSS.\
**Not included in the review**\
CD4 count.ART side effects by Side Effects Checklist.ART adherence by percentage.Notes**Setting:** not reported\
**Country:** USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"Randomization was performed in blocks of six using the SAS system's PLAN procedure\".Allocation concealment (selection bias)Unclear riskThe trial authors did not describe any selection bias.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesLow riskLosses to follow‐up: 7.5% intervention group versus 5.6% control.Selective reporting (reporting bias)Low riskWe did not detect any other potential sources of selection reporting bias.Other biasLow riskNo differences between groups at baseline except for viral load and this was controlled for.[@CD010806-bbs2-0008]Methods**Trial design:** 2‐arm follow‐up\
**Follow‐up:** baseline, 2 months post, and 6 months follow‐up\
**Loss to follow‐up:** 21 participants discontinued the interventionParticipants**Population:** 117 homosexual male participants, intervention =78, control = 39\
**Inclusion criteria:** male, aged 18 to 70 years, living within 1 hour of the hospital, and having a diagnosis of HIV\
**Exclusion criteria:** (1) subjects with active current major depression, substance abuse, or significant cognitive deficit.Interventions**Treatment:** N = 78. Mindfulness‐Based Stress Reduction (MBSR): participants were taught mindfulness skills geared towards enhancing their awareness of and relation to current experience rather than focusing on the content and reappraisal of thoughts and interpretations of experiences.\
Group size: 14 to 18.Facilitators: no details given.Session duration: 3 hours.Session frequency: 8 weekly sessions.Addiditional components: a day‐long retreat with an hour daily homework.\
**Control:** N = 39. Treatment as Usual (TAU) group offered at end of interventionOutcomes**Included in review**\
Stress by Impact of Event Scale (IES).Anxiety by Hospital Anxiety and Depression Scale (HADS).Depression by HADS.\
**Not included in review**\
Mood by Positive and Negative Affect Schedule (PANAS).Mindfulness by the Toronto Mindfulness Scale (TMS).NotesHomosexual population\
Ethics reviewed.\
**Setting:** hospital\
**Country:** Toronto, Canada***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"A randomization free‐ware, software program (Network, 1997) was utilized to generate a random allocation sequence 2:1 in favour of the group intervention for each cohort of up to 30 eligible participants\".Allocation concealment (selection bias)Unclear riskQuote: \"study staff were not aware of a potential participant's group member‐ ship until the whole cohort was assigned at the same time\". The trial authors did not provide any further details.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 24.4% intervention group versus 5.1% control. ITT analysis done.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0009]Methods**Trial design:** 3‐arm RCT\
**Follow‐up:** baseline, post, 4 months, and 8 months follow‐up\
**Loss to follow‐up:** 73%; 68%, 82%Participants**Population:** 299 adults, intervention = 84, control = 107\
**Inclusion:** 18 years or older, provision of written consent, a self reported diagnosis of HIV AIDS, and residence in a community of 50,000 people or fewer that was at least 20 miles from a city of 100,000 or more.\
**Exclusion:** there were no exclusion related to psychological functioning.Interventions**Treatment:** N = 108. Coping improvement group intervention used cognitive behavioural principles to appraise stressor severity, develop adaptive problem‐ and emotion‐focused coping skills, and optimize coping through the appropriate use of personal and social resources.\
Group size: 6 to 8.Facilitators: Master\'s degree level in psychology or social work.Session duration: 90 minutes.Session frequency: 8 sessions.\
**Treatment:** N = 84. Information Support Group provided information on HIV symptom management, nutrition and HIV, exercise and HIV, and discussions of personal topics.\
Group size: 6 to 8 participants per group.Facilitators: conducted using teleconference technology and co‐facilitated by nurse practitioners or social workers.Session duration: 90 minutes.Session frequency: 8 sessions.\
**Control:** N = 107. Usual care condition received no intervention but had access to usual servicesOutcomes**Included in review**\
Depression by BDI.Life stressors by HIV‐Related Life Stressor Burden Scale (HRLSBS).Coping by Coping Self‐Efficacy Scale.\
**Not included in review**\
Psychological symptoms by Symptom Checklist 90‐Revised (SCL‐90‐R).Emotional and social well‐being by Funtional Assessment of HIV Infection Inventory (FAHI).Barriers to care by Barriers to Care Scale (BACS).Social Support by Provision of Social Relations Scale (PSRS).Notes**Setting:** telephone‐delivered\
**Country:** USA\
Groups conducted separately for MSM, heterosexual men, and women\
71% reporting moderate to severe depression at baseline.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors described the trial as \"randomized\" but did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 18.5 intervention group versus 27.1% control. ITT done. A last‐observation‐carried‐forward (LOCF) approach was used to input missing data.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0010]Methods**Trial design:** 3‐arm RCT\
**Follow‐up:** baseline, post, 4 months, and 8 months follow‐up\
**Loss to follow‐up:** coping group 79% loss, interpersonal support group 69% loss, individual therapy group 86% loss.Participants**Population:** 295 men and women over the age of 50, intervention = 104, control = 105.\
**Inclusion:** 50 years or older, a diagnosis of HIV infection or AIDS, a BDI‐II score of 10 or higher, a score of 75 or more on the 3MS, a minimum value of 10 on the BDI‐II. (A minimum value of 10 on the BDI‐II was used to ensure that participants had a minimally elevated number of depressive symptoms that had the potential to be reduced by the interventions).\
**Exclusion:** the project did not exclude individuals with alcohol or substance use disorders, active bipolar disorder, psychotic symptoms, or individuals receiving psychotherapy.Interventions**Treatment:** N = 104. Coping improvement group intervention addressed introductions and participants\' sharing of personal histories (Session 1 and 2) appraisal and changeability of stressors related to one\'s HIV infection and stressors related to normal ageing (Sessions 3 and 4); developing and implementing adaptive problem‐ and emotion‐focused coping skills (Sessions 5 through 9); optimizing coping efforts through the use of interpersonal supports (Session 10 and 11); and termination issues and voluntary sharing of personal contact information (Session 12)\
Group size: 6 to 8 participants.Facilitators: Master\'s degree level in psychology or social work and had provided mental health support services to persons living with HIV AIDS for more than 10 years.Session duration: 90 minutes.Session frequency: 12 weeks.\
**Treatment:** N = 105. Interpersonal Support Group of 12 x 90‐minute group sessions (5 minutes spent on viewing and discussing videotapes on HIV‐related topics of nutrition, treatment, adherence, sexual risk reduction, 45 minutes spent discussing how the sessions\' topic pertained to their personal lives).\
Facilitators: 2 Masters‐level clinicians\
**Control:** N = 86. Individual Therapy Upon Request (ITUR) Group had access to standard psychosocial community‐based services.Outcomes**Included in review**\
Depression by Geriatric Depression Scale (GDS).\
**Not included in the review**\
None.Notes**Setting:** community\
**Country:** Ohio and New York, USA.\
Each 90‐minute group conducted separately for MSM, heterosexual men, and women.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors described the trial as \"randomized\" but did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 15.4% intervention group versus 31.4% control.Selective reporting (reporting bias)Low riskWe did not detect any selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0011]Methods**Trial design**: 2‐arm RCT\
**Follow‐up:** pre, post, 12 months\
**Loss to follow‐up:** not reported.Participants**Population:** 451 minority women, intervention = 212, control = 239\
**Inclusion:** 18 years and older, meet the CDC classification for case‐defined AIDS (i.e. CD4+ cell count below 200/mm² and/or one opportunistic infection, CDC 1993), have at least 6th grade education\
**Exclusion:** women with psychiatric, neuropsychiatric or medical conditions were temporarily excluded pending treatment.Interventions**Treatment:** N = 212. Cognitive Behavioural Stress Management: sessions included didactic components on the physiological effects of stress, cognitive behavioural interpretation of stress and emotions, identification of cognitive distortions and automatic thoughts, rational thought replacement, coping skills training, assertiveness training, anger management, and identification of social support.\
Group size: not stated.Facilitators: not described.Session duration: 120 minutes (30 mins relaxation component and 90 mins stress management component).Session frequency: 10 weekly sessions.Additional components: expressive support therapy addressing: needs for mutual support, improved family and social support, emotional expressiveness, normalization of experiences, integration of changed body image, doctor‐patient relationship, and death and dying issues\
**Control:** N = 239. Individual 120‐minute information education sessions delivered by videotape covering stress management, relaxation, and coping with HIV. 10 sessionsOutcomes**Included in this review**\
Depression by BDI.Anxiety by STAICoping Self efficacy by Cognitive Behavioral Self efficacy (CB‐SE).\
**Not included in this review**\
Socio‐demographic characteristics.Notes**Setting:** medical school setting and community health centres\
**Country:** USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a table of random numbers to randomize participants to treatment.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 45.1% intervention group versus 36.9% control.Selective reporting (reporting bias)Low riskWe did not detect any potential source of selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0012]Methods**Trial design**: 3‐arm RCT\
**Follow‐up:** pre, post, and 6 months\
**Loss to follow‐up:** 69% follow‐up at 6 monthsParticipants**Population:** 148 individuals diagnosed with HIV disease (119 men, 29 women). Intervention = 59, support group = 3, Waitlist = 36\
**Inclusion:** (1) 18 years of age, (2) able to read and speak English, (3) previously aware of their HIV diagnosis, (4) deemed capable of attending intervention sessions and completing 6 months follow‐up.\
**Exclusion:** (1) no significant psychiatric illness, (2) no cognitive impairment, (3) not pregnant or taking steroids.Interventions**Treatment 1:** N = 59. CBSM focused on breathing, PMR, yoga‐form stretching, guided imagery, and beginning meditation, along with cognitive restructuring techniques and active coping skills.\
Group size: 6 to 10 participants.Facilitators: Trial authors did not describe characteristics of the facilitators.Session duration: 90 minutes.Session frequency: 8 weekly.\
**Treatment 2:** N = 43. SSG focused on facilitating communication related emotional issues, problem‐solving and cognitive‐reframing techniques, and individual and group empowerment\
Group size: 6 to 10 participants.Facilitators: facilitated by mental health nurse.Session duration: 90 minutes.Session frequency: 8 weekly.\
**Control:** N = 36. Waitlist groupOutcomes**Included in this review**\
Stress with Mishel Uncertainity in Illness Scale (MUIS).Coping by Dealing with Illness Scale (DIS).\
**Not included in this review**\
Social support by Social Provisions Scale (SPS).Psychological distress by Impact of Events Scale (IES).Overall quality of life by Functional Assessment of HIV Infection scale (FAHI).Neuroendocrine indicators of stress by cortisol and DHEA levels.Health Status by revised HIV Center Medical Staging System (rHCMSS).CD4 by immunophenotyping.NK cell cytotoxicity by cell samples.Cytokines levels using enzyme‐linked immunosorbent assay (ELISA) kits.Viral load by HIV monitor assay.Notes**Setting**: Trial authors did not describe the setting.\
**Country:** USA\
Separate gender groups, interaction terms included by group by gender***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote: \"Quota sampling was used to achieve appropriate sample representation by gender, at a ratio of 4 males:1 female (20%)\". The trial authors did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 27.1% intervention group versus 27.8% control.Selective reporting (reporting bias)Low riskWe did not detect any potential source of selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0013]Methods**Trial design:** 2‐arm RCT\
**Follow‐up:** baseline, immediately post, 6 months follow‐up\
**Loss to follow‐up:** 23% in intervention group, 21% lost in control groupParticipants**Population:** 109 HIV‐positive individuals (peasant farmers) with major depression, intervention = 57, control = 52\
**Inclusion:** 19 years or older, met the MINI International Neuropsychiatric Interview criteria for major depression, from an urban HIV care centre, were antidepressant naive\
**Exclusion:** individuals with severe medical disorder such as pneumonia or active tuberculosis, psychotic symptoms, and hearing or visual impairmentInterventions**Treatment:** N = 57. Group Support Psychotherapy (GSP) is a culturally sensitive intervention that aims to treat depression by enhancing social support, teaching coping skills and income generating skills\
Group size: 10 to 12 participants (gender specific groups).Facilitators: Mental Health workers with mental health diploma or degree, of the same gender as group.Session duration: 2 to 3 hours.Session frequency: 8 weekly sessions.\
**Control:** N=52. Active treatment group receives Group HIV education (GHE) immediately post intervention and 6 months later.Outcomes**Included in the review**\
Depression by Self Reported Questionnaire (SRQ‐20).\
**Not included in review**\
Functioning levels assessed using a locally developed scale.Percieved social support (Multi‐dimensional social support scale).Self Esteem (Rosenberg self esteem scale).Notes**Setting:** HIV care centre, urban\
**Country:** Uganda\
Gender‐specific groups***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors performed randomization by urn with a ratio of 1:1. The trial authors did not provide any further details or properties of this method.Allocation concealment (selection bias)Unclear riskMen and women separately picked a paper containing the intervention allocation from a basket, ratio. The trial authors did not provide further details on allocation concealment.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 22.8% intervention group versus 21.2% control.Selective reporting (reporting bias)Low riskWe did not detect any potential source of selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0014]Methods**Trial design:** 2 arm RCT\
**Follow‐up:** baseline, 1 month, 4 months\
**Loss to follow‐up:** 147 follow‐up (96.7% follow‐up); 3.9% attrition in MAI and 2.6% attrition in SCParticipants**Population:** 152 HIV‐positive individuals on ART with an adherence problem, intervention = 76, control = 72\
**Inclusion:** 18 years or older, new ARV medication users (2 to 24 months of ARV use)\
**Exclusion:** Trial authors did not describe any exclusion criteria.Interventions**Treatment**: N = 76. Medication adherence intervention (MAI) is medication information combined with problem‐solving skills in an experiential/interactive group format.\
Group size: 10 participants.Facilitators: MAI led by a trained lay health worker and adherence counsellor.Session duration: 1 hour a month.Session frequency: 3 months.\
**Control:** N = 76. Practitioner medical directive (standard of care; 20 min) led by medical physician. Patients individually attended monthly 1 visit to review their health status with their medical practitioner.Outcomes**Included in this review**\
Depression measured by BDI‐II\
**Not included in this review**\
The Life‐Windows Information‐Motivation‐Behavioural Skills ART adherence questionnaire.CD4 count was obtained from medical chart.Notes**Setting**: hospital\
**Country**: South Africa.\
Short follow‐up of 3 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskQuote: \"Participants were randomized into study condition using a table of random numbers following their baseline assessment\".Allocation concealment (selection bias)Unclear riskThe trial authors did not describe any selection bias, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesLow riskLosses to follow‐up: 3.9% intervention group versus 2.6% control. Trial authors performed an intention‐to‐treat analysis.Selective reporting (reporting bias)Low riskWe did not detect any potential source of selective reporting bias.Other biasLow riskWe did not detect any other sources of bias.[@CD010806-bbs2-0015]Methods**Trial design**: 2‐arm RCT\
**Follow‐up:** 3 months, 6 months and 12 months\
**Loss to follow‐up:** 84% follow‐up to at least one follow‐up assessmentParticipants**Population:** 89 HIV individuals prescribed ARVS and with a history of injection drug use, intervention = 44, control = 45\
**Inclusion:** aged 18 to 65 years, HIV‐positive, prescribed ARVs, endorsed history of injection drug use, currently enrolled in opoid treatment for at least one month, and met criteria for a diagnosis of current or subsyndromal depressive mood disorder\
**Exclusion: i**ndividuals with any active untreated or unstable major mental illness, inability or unwillingness to provide informed consent, or current participation in a CBT for depression.Interventions**Treatment:** N = 44. CBT‐AD included Life Steps, psychoeducation about HIV and depression, motivational interviewing for behaviour change, behavioural activation to increase pleasurable activities, training in adaptive thinking, problem solving, PMR, and diaphragmatic breathing.\
Group size: not statedFacilitators: pre‐ and postdoctoral clinical psychologists.Session duration: 50 minutes.Session frequency: 8 sessions over 3 months.\
**Control:** N = 45. Enhanced Treatment As Usual (ETAU) with a letter to medical provider documenting participants depression and suggesting continued assessment and treatment.\
Both treatment conditions received a single‐session intervention on medication adherence (Life Steps) with involved 11 informational, problem‐solving and cognitive‐behavioural steps.Outcomes**Included in this review**\
Depression by BDI and Montgomery‐Asberg Depression Rating Scale.\
**Not included in this review**\
Clinical Global Impression ‐ a rating of global distress and impairment for depression and substance abuse.Adherence by MEMS.CD4.Notes**Setting:** methadone clinics\
**Country:** Boston, USA***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskQuote \"Random assignment in block of 2 ‐ stratified by sex, depression severity and adherence\". The trial authors did not provide any further details.Allocation concealment (selection bias)Unclear riskQuote: \"Assignment to study condition (CBT‐AD or ETAU) was concealed from both study therapists and participants until the conclusion of the first counseling visit (see below)\". The trial authors did not provide any further details.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesLow riskAn independent assessor who was blinded to the trial conditions assessed depression.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 18.2% intervention group versus 33.3% control.Selective reporting (reporting bias)Low riskWe did not detect any potential sources of selective reporting bias.Other biasUnclear riskSmall sample size of 89. CD4 count differed at baseline but controlled for in analysis[@CD010806-bbs2-0016]Methods**Trial design:** 3‐arm RCT\
**Follow‐up:** baseline, post, 4, 8, 12 months\
**Loss to follow‐up:** minimal loss to follow‐up, ITT analysis doneParticipants**Population:** 247 HIV‐positive men (N = 117) and women (N = 130), intervention = 124, control = 123\
**Inclusion:** sexual abuse as a child (age 12 and under) and/or adolescent (age 13 to 17 years); current age of 18 or older; HIV serostatus\
**Exclusion:** acute distress due to sexual revictimization experienced within past month; presence of impaired mental status; extreme distress or depressive symptomatologyInterventions**Treatment 1:** N= 124. HIV and Trauma Coping Group Intervention (LIFT) where participants Identify stressors that they perceived to be related to their sexual abuse experiences and those related to their HIV diagnosis, learn adaptive coping and risk reduction skills related to both sexual abuse and HIV infection.\
Group size: 6‐10Facilitators: coping group lead by 2 clinical psychologists and 2 social workers. Support group lead by 4 social workers.Session duration: 90 minutes.Session frequency: 15 weekly sessions.\
**Control:** N = 123. HIV standard therapeutic support group. The comparison intervention paralleled a standard therapeutic support group and was led by experienced co‐therapists not trained on the coping intervention model. The purpose of the group was to provide a supportive environment for participants to address issues of HIV and trauma.Outcomes**Included in this review**\
Traumatic Stress by the Impact of Events Scale (IES).Avoidant coping by the Coping with AIDS ScaleWays of Coping Questionnaire (WOCQ).\
**Not included in this review**\
Condom use by frequency of unprotected vaginal and anal intercourse with all partners in last month.Notes**Setting:** Community Health Centre\
**Country:** USA\
Different populations in each report***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors described the trial as \'randomized\' but did not provide any further details.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment, if any.Blinding of participants and personnel (performance bias) AnxietyUnclear riskThe trial authors did not describe the method of blinding, if any.Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe trial authors did not describe the method of blinding, if any.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up: 16.5% Intervention group versus 33.3% control. The trial authors conducted an intention‐to‐treat analysis.Selective reporting (reporting bias)Low riskWe did not detect any other sources of selective reporting bias.Other biasLow riskWe did not detect any other potential sources of bias.[^10]

Characteristics of excluded studies \[ordered by study ID\] {#CD010806-sec2-0022}
===========================================================

StudyReason for exclusion[@CD010806-bbs2-0017]No 3‐month follow‐up post intervention.[@CD010806-bbs2-0018]Individual psychoeducational intervention, not a group intervention.[@CD010806-bbs2-0019]No specified outcomes reported. The study measured salivary cortisol as a biomarker of immune function.[@CD010806-bbs2-0020]Individual counselling sessions, not a group intervention.[@CD010806-bbs2-0021]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0022]Not a group‐based intervention.[@CD010806-bbs2-0023]No specified outcomes measured.[@CD010806-bbs2-0025]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0026]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0024]Nurse‐patient intervention, not a group intervention.[@CD010806-bbs2-0027]Overview of intervention, not a randomized controlled trial (RCT).[@CD010806-bbs2-0028]Only formative qualitative data presented, not a RCT.[@CD010806-bbs2-0029]We contacted the study author. This was not a group intervention.[@CD010806-bbs2-0030]Individual therapy for patient‐partner dyads. This was not a group intervention.[@CD010806-bbs2-0031]No 3‐month follow‐up postintervention, only 3‐month follow‐up after baseline.[@CD010806-bbs2-0032]Individual, not a group intervention.[@CD010806-bbs2-0033]No specified outcomes.[@CD010806-bbs2-0034]No 3‐month postintervention follow‐up.[@CD010806-bbs2-0035]No specified outcomes included.[@CD010806-bbs2-0036]No RCT result reported, only baseline data reported.[@CD010806-bbs2-0037]No post 3‐month follow‐up.[@CD010806-bbs2-0038]Not a group intervention.[@CD010806-bbs2-0039]Measured positive affect and positive mood. These are not specified outcomes.[@CD010806-bbs2-0040]Not a RCT as no control group.[@CD010806-bbs2-0041]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0042]Describes intervention development and components, not a RCT.[@CD010806-bbs2-0043]Nurse‐patient intervention, not a group intervention.[@CD010806-bbs2-0044]Treatment supporter intervention, not a group intervention.[@CD010806-bbs2-0045]The study author presented a subgroup analysis only, a subgroup from the larger [@CD010806-bbs2-0011] study.[@CD010806-bbs2-0046]Not a HIV‐positive population.[@CD010806-bbs2-0047]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0048]Not a RCT and no control group.[@CD010806-bbs2-0049]Not a group intervention.[@CD010806-bbs2-0050]Not a group intervention.[@CD010806-bbs2-0051]No specified outcomes reported.[@CD010806-bbs2-0052]Interpersonal therapy, not a group intervention.[@CD010806-bbs2-0053]Not truly randomized.[@CD010806-bbs2-0054]Not a RCT, quasi‐experimental.[@CD010806-bbs2-0055]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0056]No RCT reported.[@CD010806-bbs2-0057]Individual therapy, not a group intervention.[@CD010806-bbs2-0058]Not a group intervention.[@CD010806-bbs2-0059]No specified outcomes reported.[@CD010806-bbs2-0060]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0061]Adolescents 12 to 17 years old.[@CD010806-bbs2-0062]No RCT reported.[@CD010806-bbs2-0063]Individual art therapy sessions, not a group intervention.[@CD010806-bbs2-0064]No RCT reported.[@CD010806-bbs2-0065]No 3‐month follow‐up postintervention, small sample size (N = 30), and unsure whether a group intervention.[@CD010806-bbs2-0066]Not a group intervention. The intervention was individually administered to each couple.[@CD010806-bbs2-0067]No 3‐months follow‐up postintervention.[@CD010806-bbs2-0068]One‐to‐one intervention by lay health workers, not a group intervention.[@CD010806-bbs2-0069]Study protocol only. No RCT data reported.[@CD010806-bbs2-0070]No specified outcomes.[@CD010806-bbs2-0071]Both individual and group formats to intervention. No effects reported for group components of intervention.[@CD010806-bbs2-0072]Control invited to cross over to intervention at 3‐months postintervention. No postintervention follow‐up of 3 months for control group.[@CD010806-bbs2-0073]Measured coping using 3 subscales of Coping Scale.[@CD010806-bbs2-0074]No specified outcomes. Used global score of broad range of psychological symptoms, did not measure depression and anxiety outcomes separately.[@CD010806-bbs2-0075]No 3‐month follow‐up postintervention.[@CD010806-bbs2-0076]Not a group‐based intervention.[@CD010806-bbs2-0077]Content analysis, no RCT reported.[@CD010806-bbs2-0078]Therapy sessions with family at home.[@CD010806-bbs2-0079]Individually administered intervention, not a group intervention.[@CD010806-bbs2-0080]Not a group intervention but home‐based individual intervention.[@CD010806-bbs2-0081]Inconsistencies in reporting of data.[@CD010806-bbs2-0082]Individual counselling sessions, not a group intervention.[@CD010806-bbs2-0083]There was unclear presentation of follow‐up data and it was unclear whether it was 3‐month or 6‐month follow‐up data. We contacted the study author but received no response.[@CD010806-bbs2-0084]Not a RCT, no control group, HIV‐positive and HIV‐negative mixed sample.[@CD010806-bbs2-0085]Individual psychotherapy, not a group intervention.[@CD010806-bbs2-0086]Not a group intervention.[^11]
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